[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 11737
1. Mosor M, Ziółkowska I, Januszkiewicz-Lewandowska D, Nowak J: Polymorphisms and haplotypes of the NBS1 gene in childhood acute leukaemia. Eur J Cancer; 2008 Oct;44(15):2226-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms and haplotypes of the NBS1 gene in childhood acute leukaemia.
  • This study verified whether polymorphisms of the NBS1 gene may influence susceptibility to the development of childhood acute leukaemia.
  • We genotyped six polymorphisms of the NBS1 gene in 157 children with acute leukaemia and 275 controls.
  • The TT genotype of c.2071-30A>T polymorphism was higher in leukaemia patients than in controls.
  • [MeSH-major] Cell Cycle Proteins / genetics. Leukemia / genetics. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. Polymorphism, Genetic
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Gene Frequency. Genetic Predisposition to Disease. Genotype. Haplotypes. Humans. Infant

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691878.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / NBN protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


2. Motohashi K, Ito S, Hagihara M, Sakai R, Tanaka M, Kawano T, Maruta A, Ishigatsubo Y, Kanamori H: Allogeneic hematopoietic stem cell transplantation after surgical resection of pulmonary aspergillosis in 5 patients with acute leukemia. Rinsho Ketsueki; 2009 May;50(5):430-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation after surgical resection of pulmonary aspergillosis in 5 patients with acute leukemia.
  • We report five patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation (HSCT) following surgical resection of pulmonary aspergillosis.
  • The causes of death included leukemia relapse in two and hemophagocytic syndrome in one.
  • These results suggest that pre-transplant surgical resection with post-transplant prophylactic antifungal agents seems to be an effective strategy to prevent the relapse of pulmonary aspergillosis in patients with residual disease in the lung before allogeneic HSCT.
  • [MeSH-major] Antibiotic Prophylaxis. Hematopoietic Stem Cell Transplantation. Leukemia / complications. Perioperative Care. Pulmonary Aspergillosis / prevention & control. Pulmonary Aspergillosis / surgery
  • [MeSH-minor] Acute Disease. Adult. Antifungal Agents / administration & dosage. Fatal Outcome. Female. Humans. Immunocompromised Host. Male. Middle Aged. Opportunistic Infections / complications. Pneumonectomy. Retrospective Studies. Secondary Prevention. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Aspergillosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483405.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


3. Suzuki H, Suzuki T, Kamijo A, Oota S, Sato H, Hangaishi A, Takahashi T, Kanda Y, Motokura T, Chiba S, Kurokawa M: Antileukemic immunity associated with antineutrophil antibody production after allogeneic hematopoietic SCT for myeloid/NK-cell precursor acute leukemia. Bone Marrow Transplant; 2008 Aug;42(4):285-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antileukemic immunity associated with antineutrophil antibody production after allogeneic hematopoietic SCT for myeloid/NK-cell precursor acute leukemia.
  • [MeSH-major] Graft vs Leukemia Effect / immunology. Hematopoietic Stem Cell Transplantation / adverse effects. Killer Cells, Natural / immunology. Leukemia, Myeloid / immunology. Neutrophils / immunology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500367.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


Advertisement
4. Li VC, Li CK: [Optimal central nervous system directed therapy in childhood acute lymphoblastic leukemia.]. Zhonghua Er Ke Za Zhi; 2007 May;45(5):339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optimal central nervous system directed therapy in childhood acute lymphoblastic leukemia.].
  • [MeSH-major] Central Nervous System / pathology. Central Nervous System Neoplasms / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697618.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Krause A, Luciana M, Krause F, Rego EM: Targeting the acute myeloid leukemia stem cells. Anticancer Agents Med Chem; 2010 Feb;10(2):104-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting the acute myeloid leukemia stem cells.
  • Nevertheless, the term leukemia stem cells (LSCs) has been adopted recently to describe these immature progenitors based on the fact that they share the most relevant features of the normal hematopoetic stem cells (HSCs), i.e. the self-renewal potential and quiescent status.
  • LSCs differ from their normal counterparts and from the more differentiated leukemic cells regarding the default status of pathways regulating apoptosis, cell cycle, telomere maintenance and transport pumps activity.
  • The aim of this review is, by taking acute myeloid leukemia (AML) as a bona fide example, to discuss some of the mechanisms used by the LSCs to survive and the strategies which could be used to eradicate these cells.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Delivery Systems / methods. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / pathology. Neoplastic Stem Cells / drug effects
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / drug effects. Cell Transformation, Neoplastic / pathology. Humans. Signal Transduction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20184541.001).
  • [ISSN] 1875-5992
  • [Journal-full-title] Anti-cancer agents in medicinal chemistry
  • [ISO-abbreviation] Anticancer Agents Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 92
  •  go-up   go-down


6. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA: Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia. Br J Haematol; 2006 Aug;134(4):445-6; author reply 446-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia.
  • [MeSH-major] Dendritic Cells / transplantation. Immunotherapy, Adoptive / methods. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Cell Culture Techniques. Humans

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Haematol. 2006 Apr;133(2):152-7 [16611305.001]
  • (PMID = 16822293.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


7. Denis L, Gagne K, Gueglio B, Kerdudou N, Milpied N, Simon P, Follea G, Bonneville M, Harousseau JL, Bignon JD: NK-KIR transcript kinetics correlate with acute graft-versus-host disease occurrence after allogeneic bone marrow transplantation. Hum Immunol; 2005 May;66(5):447-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK-KIR transcript kinetics correlate with acute graft-versus-host disease occurrence after allogeneic bone marrow transplantation.
  • Natural killer (NK) cell alloreactivity observed during stem cell transplantation (SCT) can be either beneficial (graft-versus-leukemia effect) or detrimental to the host (graft-versus-host disease).
  • Killer immunoglobulin-like receptors (KIRs), expressed on NK and CD8 memory T cells, are regulated at a posttranscriptional level and, because there are currently no KIR-specific antibodies available, the analysis of these receptors remains elusive.
  • Groups I and III were characterized by the absence or a delayed appearance of KIR transcripts, which correlated with the highest risk of acute graft-versus-host disease (aGvHD).
  • [MeSH-major] Bone Marrow Transplantation / immunology. Graft vs Host Disease / immunology. Killer Cells, Natural / immunology. Receptors, Immunologic / genetics. Transplantation, Homologous / immunology
  • [MeSH-minor] Adolescent. Adult. Blood Cell Count. CD8-Positive T-Lymphocytes / cytology. Cell Membrane / metabolism. Female. Gene Expression / genetics. Gene Expression / immunology. Genotype. Humans. Hypoxanthine Phosphoribosyltransferase / genetics. Kinetics. Male. Middle Aged. Receptors, KIR. Receptors, KIR2DL4. Receptors, KIR3DL1. Receptors, KIR3DL2. Transcription, Genetic / genetics. Transcription, Genetic / immunology. Transplantation Conditioning

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15935882.001).
  • [ISSN] 0198-8859
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Immunologic; 0 / Receptors, KIR; 0 / Receptors, KIR2DL4; 0 / Receptors, KIR3DL1; 0 / Receptors, KIR3DL2; EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase
  •  go-up   go-down


8. Schrøder H, Kjeldahl M, Boesen AM, Nielsen OJ, Schmidt K, Johnsen HE, Gregersen H, Heyman M, Gustafsson G: Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication. Dan Med Bull; 2006 Feb;53(1):76-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication.
  • INTRODUCTION: Data seem to indicate that young adults with acute lymphoblastic leukemia (ALL) have a better survival when treated with pediatric protocols compared with adult ALL protocols.
  • RESULTS: There were no difference with respect to the distribution of T-ALL, CNS-leukemia, total white blood count and high risk chromosomal abnormalities between the two groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Neoplasm Recurrence, Local. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Stem Cell Transplantation. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761337.001).
  • [ISSN] 1603-9629
  • [Journal-full-title] Danish medical bulletin
  • [ISO-abbreviation] Dan Med Bull
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


9. Sikora P, Borzecka H, Kołłataj B, Majewski M, Wieczorkiewicz-Płaza A, Zajaczkowska M: [The diagnosis of familial hypomagnesemia with hypercalciuria and nephrocalcinosis in a girl with acute lymphoblastic leukemia--case report]. Pol Merkur Lekarski; 2006 Apr;20(118):430-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The diagnosis of familial hypomagnesemia with hypercalciuria and nephrocalcinosis in a girl with acute lymphoblastic leukemia--case report].
  • We present 16-year old girl in whom symptoms of FHHNC were accidentally recognized during therapy of acute lymphoblastic leukemia.
  • To the best of our knowledge, this is the first report of FHHNC associated with acute lymphoblastic leukemia.
  • [MeSH-major] Hypophosphatemia, Familial / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Nephrocalcinosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886568.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


10. Zintzaras E, Koufakis T, Ziakas PD, Rodopoulou P, Giannouli S, Voulgarelis M: A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia. Eur J Epidemiol; 2006;21(7):501-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia.
  • A meta-analysis of case-control studies that investigated the association between the C677T and/or A1298C polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene and acute lymphoblastic leukemia (ALL) was carried out.
  • Pooled odds ratios (OR) of various genetic contrasts of each polymorphism were estimated using random (RE) and fixed effects (FE) models.
  • The recessive model for allele 1298C produced a rather marginal association: RE OR: 0.67; 95% confidence interval (CI): 0.46-0.99 and FE OR: 0.64; 95% CI: 0.49-0.84.
  • In childhood ALL, according to the results of the allele contrast and the recessive model for 677T allele it was conceivable that a protective effect exist: RE OR = 0.74; 95% CI: 0.57-0.96 and RE OR: 0.69; 95% CI: 0.51-0.94, respectively.
  • [MeSH-major] Genotype. Haplotypes / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Epidemiol. 2006;21(12):885-6 [17203359.001]
  • [Cites] Annu Rev Nutr. 1999;19:217-46 [10448523.001]
  • [Cites] Blood. 2004 Jan 1;103(1):252-7 [12958073.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3290-5 [9096386.001]
  • [Cites] Blood. 2002 May 15;99(10):3786-91 [11986237.001]
  • [Cites] Stat Med. 1997 Dec 30;16(24):2901-13 [9483722.001]
  • [Cites] J Hum Genet. 2004;49(9):474-81 [15368102.001]
  • [Cites] Clin Genet. 2006 Apr;69(4):327-36 [16630166.001]
  • [Cites] Lancet. 2003 Feb 15;361(9357):567-71 [12598142.001]
  • [Cites] Genet Epidemiol. 2005 Feb;28(2):123-37 [15593093.001]
  • [Cites] Biometrics. 1994 Dec;50(4):1088-101 [7786990.001]
  • [Cites] Trends Mol Med. 2003 Apr;9(4):135-8 [12727138.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Aug;27(8):425-9 [16096524.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1044-51 [9545395.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2033-41 [15141041.001]
  • [Cites] Mol Genet Metab. 1998 Jul;64(3):169-72 [9719624.001]
  • [Cites] N Engl J Med. 1975 Mar 6;292(10):491-6 [1117892.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1709-14 [9328165.001]
  • [Cites] BMC Med Genet. 2005 May 27;6:23 [15921520.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):447-62 [10953966.001]
  • [Cites] Eur J Hum Genet. 2001 Aug;9(8):583-9 [11528503.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Jun;22(6):645-8 [10837359.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):147-51 [16123993.001]
  • [Cites] Cancer Sci. 2005 Sep;96(9):535-42 [16128738.001]
  • [Cites] Trends Pharmacol Sci. 2001 Apr;22(4):195-201 [11282420.001]
  • [Cites] Am J Epidemiol. 2003 Apr 1;157(7):571-82 [12672676.001]
  • [Cites] Hepatology. 2006 Feb;43(2):352-61 [16440362.001]
  • [Cites] Am J Epidemiol. 1999 Apr 15;149(8):706-11 [10206619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4004-9 [11274424.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Haematologica. 2004 Feb;89(2):139-44 [15003888.001]
  • [Cites] Nat Genet. 1995 May;10(1):111-3 [7647779.001]
  • [Cites] J Hum Genet. 2005;50(6):267-75 [15902512.001]
  • [Cites] J Nutr. 2002 Sep;132(9):2792-8 [12221247.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):154-60 [12827651.001]
  • [Cites] Bioinformatics. 2005 Sep 15;21(18):3672-3 [15955784.001]
  • [Cites] Osteoporos Int. 2004 Sep;15(9):729-34 [15057510.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1701-7 [9057653.001]
  • [Cites] Hum Genet. 2002 Dec;111(6):573-4 [12516594.001]
  • [Cites] Am J Hum Genet. 1991 Mar;48(3):536-45 [1998339.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):616-8 [11736945.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1356-60 [11684236.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2042-9 [15141042.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):306-9 [11600885.001]
  • [Cites] J Clin Epidemiol. 2005 Jun;58(6):543-9 [15878467.001]
  • [Cites] BMJ. 1997 Sep 13;315(7109):629-34 [9310563.001]
  • [Cites] Am J Epidemiol. 2006 Feb 15;163(4):300-9 [16410351.001]
  • [Cites] Psychiatr Genet. 2006 Jun;16(3):105-15 [16691128.001]
  • [Cites] J Hum Genet. 2005;50(2):84-91 [15682272.001]
  • [Cites] J Hum Genet. 2006;51(7):618-24 [16758123.001]
  • [Cites] Am J Epidemiol. 2000 May 1;151(9):862-77 [10791559.001]
  • [Cites] J Adv Nurs. 2002 May;38(3):274-80 [11972663.001]
  • [Cites] Lancet. 1995 Oct 21;346(8982):1070-1 [7564788.001]
  • [Cites] N Engl J Med. 1992 Jul 23;327(4):248-54 [1614465.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • [Cites] Lancet. 1998 Jan 10;351(9096):123-7 [9439507.001]
  • (PMID = 16897583.001).
  • [ISSN] 0393-2990
  • [Journal-full-title] European journal of epidemiology
  • [ISO-abbreviation] Eur. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


11. Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB: Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer; 2009 Aug;53(2):162-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
  • BACKGROUND: Asparaginase, an agent used in the treatment of acute lymphoblastic leukemia (ALL), is associated with the development of pancreatitis.
  • Sixteen (57%) patients were re-treated with asparaginase, 10 of whom had another episode of pancreatitis.
  • CONCLUSION: Asparaginase-associated pancreatitis was more common in older children, and caused significant acute morbidity.
  • Re-treatment with asparaginase after an episode of pancreatitis was associated with a high risk of recurrent pancreatitis.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Med Pediatr Oncol. 2000 Mar;34(3):200-5 [10696127.001]
  • [Cites] Pediatr Blood Cancer. 2007 Oct 15;49(5):634-9 [16937362.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Dis Markers. 2001;17(2):77-88 [11673654.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):237-46 [11773175.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1986-94 [11877270.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2734-9 [11929760.001]
  • [Cites] Science. 1968 May 3;160(3827):533-5 [5689413.001]
  • [Cites] J Exp Med. 1968 Jun 1;127(6):1055-72 [4871211.001]
  • [Cites] N Engl J Med. 1969 Nov 6;281(19):1028-34 [4898857.001]
  • [Cites] Cancer. 1970 Feb;25(2):306-20 [4905155.001]
  • [Cites] Cancer Res. 1971 Jul;31(7):942-9 [4327086.001]
  • [Cites] Biochem Pharmacol. 1969 Oct;18(10):2578-80 [4935103.001]
  • [Cites] Cancer. 1972 Aug;30(2):339-47 [4626307.001]
  • [Cites] J Pediatr. 1972 Dec;81(6):1220-1 [4643049.001]
  • [Cites] Cancer. 1974 Sep;34(3):780-5 [4527863.001]
  • [Cites] Med Pediatr Oncol. 1976;2(4):387-95 [1004382.001]
  • [Cites] Med Pediatr Oncol. 1977;3(4):387-400 [337095.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1979 Spring;1(1):9-13 [295576.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5601-7 [6352020.001]
  • [Cites] N Engl J Med. 1986 Sep 11;315(11):657-63 [2943992.001]
  • [Cites] Br J Haematol. 1990 Apr;74(4):465-70 [2189489.001]
  • [Cites] Eur J Haematol. 1992 Aug;49(2):63-6 [1397242.001]
  • [Cites] Thromb Haemost. 1993 Jan 11;69(1):12-5 [8446931.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):740-7 [8151317.001]
  • [Cites] Blood. 1997 Mar 15;89(6):1886-95 [9058708.001]
  • [Cites] Blood. 2007 Feb 1;109(3):896-904 [17003366.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2247-56 [11187916.001]
  • (PMID = 19405141.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA068484-13; United States / NCI NIH HHS / CA / P01 CA068484-13; United States / NCI NIH HHS / CA / P01 CA068484-139001; United States / NCI NIH HHS / CA / CA068484-139001; United States / NCI NIH HHS / CA / P01 CA068484; United States / NCI NIH HHS / CA / 5P01CA68484
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  • [Other-IDs] NLM/ NIHMS110197; NLM/ PMC2721691
  •  go-up   go-down


12. Li XL, Arai Y, Harada H, Shima Y, Yoshida H, Rokudai S, Aikawa Y, Kimura A, Kitabayashi I: Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription. Oncogene; 2007 Nov 8;26(51):7231-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription.
  • The AML1 transcription factor complex is the most frequent target of leukemia-associated chromosomal translocations.
  • In the current study, we screened mutations of the HIPK2 gene in 50 cases of acute myeloid leukemia (AML) and in 80 cases of myelodysplastic syndrome (MDS).
  • These findings suggest that dysfunction of HIPK2 may play a role in the pathogenesis of leukemia.
  • [MeSH-major] Carrier Proteins / genetics. Core Binding Factor Alpha 2 Subunit / physiology. Leukemia, Myeloid, Acute / genetics. Mutation, Missense. Myelodysplastic Syndromes / genetics. Protein-Serine-Threonine Kinases / genetics. Transcription, Genetic / physiology. Tumor Suppressor Protein p53 / physiology
  • [MeSH-minor] Base Sequence. Cell Line. DNA Primers. Humans. Subcellular Fractions / metabolism


13. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ: Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood; 2006 Aug 1;108(3):1092-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.
  • A sequential regimen of chemotherapy, reduced-intensity conditioning (RIC) for allogeneic stem cell transplantation (SCT), and prophylactic donor lymphocyte transfusion (pDLT) was studied in 103 patients with refractory acute myeloid leukemia (AML).
  • Patients without graft-versus-host disease (GvHD) at day +120 received pDLT in escalating doses.
  • Before conditioning, 99 patients had active disease, 3 were aplastic, 1 was in second complete remission (CR2).
  • With a 25-month median follow-up, overall survival (OS) at 1, 2, and 4 years was 54%, 40%, and 32%; the respective leukemia-free survival (LFS) was 47%, 37%, and 30%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Salvage Therapy / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Combined Modality Therapy. Female. Graft vs Host Disease. Humans. Lymphocyte Transfusion. Male. Middle Aged. Survival Analysis. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551971.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


14. Miao K, Li J, Qiu H, Zhang R, Chen L, Wu H, Wang R, Zhang J: The chromosomal translocation (11;14) (p13; q11) in acute B-Cell lymphocytic leukemia. Onkologie; 2010;33(7):385-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The chromosomal translocation (11;14) (p13; q11) in acute B-Cell lymphocytic leukemia.
  • BACKGROUND: Cytogenetic abnormalities are the most important independent prognostic factors of acute leukemia and imply the potential molecular mechanism of the disease.
  • Translocation (11;14)(p13;q11) has been predominantly found in T-cell acute lymphocytic leukemia (ALL) but is rare in B-cell ALL.
  • CASE REPORT: We present the case of a 30-year-old male patient, who presented with symptomatic anemia, thrombocytopenia and leukocytosis.
  • CONCLUSIONS: Translocation (11;14) (p13;q11) in B-cell ALL is rare, but it is worth exploring the molecular mechanisms and discovering the prognostic value in more B-cell ALL patients.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 14 / genetics. Leukemia, B-Cell / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Chromosome Banding. Disease Progression. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Male. Prognosis. Remission Induction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20631486.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


15. Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, Fung S, Schlenk RF, Dohner K, Hinrichsen T, Rudolph C, Schambach A, Baum C, Schlegelberger B, Dohner H, Ganser A, Humphries RK: MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood; 2007 Sep 1;110(5):1639-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML.
  • Overexpression of wild-type MN1 is a negative prognostic factor in patients with acute myeloid leukemia (AML) with normal cytogenetics.
  • MN1 increased resistance to all-trans retinoic acid (ATRA)-induced cell-cycle arrest and differentiation by more than 3000-fold in vitro.
  • The differentiation block could be released by fusion of a transcriptional activator (VP16) to MN1 without affecting the ability to immortalize BM cells, suggesting that MN1 blocks differentiation by transcriptional repression.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Drug Resistance, Neoplasm. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / metabolism. Leukemia, Myeloid, Acute / mortality. Repressor Proteins / biosynthesis. Tumor Suppressor Proteins / biosynthesis
  • [MeSH-minor] Aged. Animals. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacology. Bone Marrow Cells / metabolism. Cell Cycle / drug effects. Cell Cycle / genetics. Cell Differentiation / drug effects. Cell Differentiation / genetics. Cell Transformation, Viral / drug effects. Cell Transformation, Viral / genetics. Chromosomal Instability / genetics. Disease-Free Survival. Hematopoiesis / drug effects. Hematopoiesis / genetics. Herpes Simplex Virus Protein Vmw65 / biosynthesis. Herpes Simplex Virus Protein Vmw65 / genetics. Humans. Male. Middle Aged. Mutagenesis, Insertional / drug effects. Mutagenesis, Insertional / genetics. Predictive Value of Tests. Recombinant Fusion Proteins / biosynthesis. Recombinant Fusion Proteins / genetics. Retroviridae. Risk Factors. Survival Rate. Transduction, Genetic. Tretinoin / administration & dosage. Tretinoin / pharmacology

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17494859.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Herpes Simplex Virus Protein Vmw65; 0 / MN1 protein, human; 0 / Recombinant Fusion Proteins; 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins; 5688UTC01R / Tretinoin
  •  go-up   go-down


16. Lowe T, Luu T, Shen J, Bhatia S, Shibata S, Stein A, Somlo G: Male breast cancer 15 years after allogeneic hematopoietic cell transplantation including total body irradiation for recurrent acute lymphoblastic leukemia. Onkologie; 2008 May;31(5):266-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast cancer 15 years after allogeneic hematopoietic cell transplantation including total body irradiation for recurrent acute lymphoblastic leukemia.
  • BACKGROUND: Over the years, the prognosis following treatment of a primary cancer has significantly improved.
  • One of the most devastating long-term complications is the development of a second malignancy.
  • CASE REPORTS: We report here the case of a 34-year-old man who developed stage IIB node-positive breast cancer almost 15 years following total body irradiation and allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia.
  • To our knowledge, this is only the second report of a male breast cancer following allogeneic bone marrow transplantation (BMT).
  • [MeSH-major] Breast Neoplasms, Male / etiology. Hematopoietic Stem Cell Transplantation / adverse effects. Neoplasms, Radiation-Induced / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Whole-Body Irradiation / adverse effects


17. Akahane D, Gotoh A, Takaku T, Iwase O, Ohyashiki K: Pseudothrombocytes detected by two-color flowcytometry in acute lymphoblastic leukemia (ALL-L3). Leuk Res; 2006 Sep;30(9):1211-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudothrombocytes detected by two-color flowcytometry in acute lymphoblastic leukemia (ALL-L3).
  • [MeSH-major] Blood Platelets / pathology. Flow Cytometry. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494943.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


18. Bakhshi S, Arya LS: Conjunctival mass: rare site of extramedually relapse in childhood acute lymphoblastic leukemia. J Assoc Physicians India; 2005 Feb;53:160-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival mass: rare site of extramedually relapse in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Conjunctiva / pathology. Conjunctival Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Assoc Physicians India. 2005 Mar;53:199. Bakhsi, S [corrected to Bakhshi, S]
  • (PMID = 15847046.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


19. Dopico Vázquez D, Gallegos Sancho MI, Alonso Curbera G, Carral Maseda A, Quindós Varela M, Antón Aparicio LM: Non-seminomatous germ-cell tumour associated with acute megakaryoblastic leukaemia. Clin Transl Oncol; 2007 May;9(5):329-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-seminomatous germ-cell tumour associated with acute megakaryoblastic leukaemia.
  • The association of mediastinal germ-cell tumours (MGCTs) with haematologic neoplasms is a rare though well known circumstance, and few cases are found in the literature.
  • The diagnosis of the haematological condition is usually either synchronic or metachronic with that of the germ-cell tumour.
  • The case report we present is that of a young male with an initial diagnosis of both conditions.
  • It was possible to apply specific treatment, initially in the case of the leukaemia, and later in the case of the germ-cell tumour.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute. Mediastinal Neoplasms. Neoplasms, Germ Cell and Embryonal. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1985 May;102(5):603-9 [2984971.001]
  • [Cites] N Engl J Med. 1990 May 17;322(20):1425-9 [2158625.001]
  • [Cites] Tumori. 1995 Jul-Aug;81(4):299-301 [8540131.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):108-14 [14701772.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 5;92(1):54-61 [10620634.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • [Cites] Hum Pathol. 1988 May;19(5):586-90 [2453444.001]
  • (PMID = 17525044.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Xu J, Suzuki M, Niwa Y, Hiraga J, Nagasaka T, Ito M, Nakamura S, Tomita A, Abe A, Kiyoi H, Kinoshita T, Naoe T: Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol; 2008 Feb;140(4):394-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome.
  • This study examined the expression of nuclear NPBC in bone marrow specimens from 54 and 44 patients with de novo acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), respectively.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Leukemia, Myeloid, Acute / metabolism. Myelodysplastic Syndromes / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Cells / metabolism. Cell Nucleus / metabolism. Chromosome Aberrations. Female. Humans. Karyotyping. Male. Middle Aged. Neoplasm Proteins / metabolism. Phosphorylation. Prognosis. Survival Analysis


21. van Grotel M, van den Heuvel-Eibrink MM, van Wering ER, van Noesel MM, Kamps WA, Veerman AJ, Pieters R, Meijerink JP: CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Dec;51(6):737-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia.
  • BACKGROUND: Children with T-lineage acute lymphoblastic leukemia (T-ALL) have an inferior outcome with combination chemotherapy compared to B-lineage ALL, and still about 30% of the patients relapse within the first 2 years following diagnosis.
  • As CD34 has been related with poor outcome in ALL in general, we investigated the prognostic significance of the stem cell marker CD34, as well as the association of CD34 positivity with the expression of several multidrug resistance (MDR) genes.
  • PROCEDURE: In this retrospective study, we investigated the prognostic significance of the expression of the early T-cell differentiation marker CD34 and the expression of MDR genes in relation to outcome in a cohort of 72 newly diagnosed pediatric T-ALL patients.
  • RESULTS: CD34 expression was related to a poor 5-year disease-free-survival and a poor 5-year overall survival.
  • [MeSH-major] Antigens, CD34 / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683236.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antigens, CD34; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1
  •  go-up   go-down


22. Garg A, Kundu RV, Plotkin O, Aronson IK: Annular elastolytic giant cell granuloma heralding onset and recurrence of acute myelogenous leukemia. Arch Dermatol; 2006 Apr;142(4):532-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Annular elastolytic giant cell granuloma heralding onset and recurrence of acute myelogenous leukemia.
  • [MeSH-major] Granuloma Annulare / diagnosis. Leukemia, Myeloid, Acute / diagnosis


23. Creutzig U, Zimmermann M, Dworzak M, Urban C, Henze G, Kremens B, Lakomek M, Bourquin JP, Stary J, Reinhardt D: Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol; 2010 May;149(3):399-409
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses.
  • Acute promyelocytic leukaemia (APL) treatment often includes high cumulative doses of anthracyclines, which can cause long-term cardiotoxicity.
  • Here, we report the favourable outcome in 81 paediatric APL patients treated according to the consecutive acute myeloid leukaemia-Berlin/Frankfurt/Muenster (AML-BFM) trials -93/-98/-2004 with an anthracycline-cytarabine regimen in combination with all-trans-retinoid acid (ATRA).
  • Salvage treatment was effective in 7/9 patients (78%) with relapsed APL, who now are long-term survivors after second line combination treatment with arsenic trioxide (4/7 patients) and stem cell transplantation (5/7 patients).
  • [MeSH-major] Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230404.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin
  •  go-up   go-down


24. Rioufol C, Coiffier B: Acute tumor lysis syndrome during oral fludarabine treatment for CLL--a rare event that might be observed more frequently in the future. Onkologie; 2008 Apr;31(4):157-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute tumor lysis syndrome during oral fludarabine treatment for CLL--a rare event that might be observed more frequently in the future.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Tumor Lysis Syndrome / etiology. Tumor Lysis Syndrome / prevention & control. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Onkologie. 2008 Apr;31(4):197-9 [18418022.001]
  • (PMID = 18418014.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Comment; Editorial; Introductory Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


25. Jin FY, Zou DH, Wang GR, Xu Y, Feng SZ, Zhao YZ, Han MZ, Yan WW, Qiu LG: [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients]. Zhonghua Xue Ye Xue Za Zhi; 2005 Nov;26(11):645-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
  • OBJECTIVE: To evaluate the effectiveness of chemotherapy (CT) and autologous hematopoietic stem cell transplantation (ASCT) as post-remission treatment for adult acute lymphoblastic leukemia (AL) patients.
  • The rates of leukemia free survival (LFS), overall survival (OS) and relapse were compared between the two groups. RESULTS:.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620547.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


26. Ferrà C, Castellví J: [Cervical adenopathy in a patient with acute leukemia and stem cell transplantation]. Med Clin (Barc); 2005 Sep 3;125(7):270-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cervical adenopathy in a patient with acute leukemia and stem cell transplantation].
  • [Transliterated title] Adenopatías laterocervicales en un paciente con leucemia aguda y trasplante de progenitores hematopoyéticos.
  • [MeSH-major] Epstein-Barr Virus Infections / diagnosis. Hepatitis, Viral, Human / diagnosis. Hepatitis, Viral, Human / etiology. Herpes Simplex / diagnosis. Leukemia, Myeloid / therapy. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / etiology. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Herpesvirus 1, Human / isolation & purification. Herpesvirus 3, Human / isolation & purification. Herpesvirus 4, Human / isolation & purification. Humans. Lymphatic Metastasis / diagnosis. Male. Neck. Necrosis. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Herpes Simplex.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137489.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


27. Holleman A, den Boer ML, Kazemier KM, Beverloo HB, von Bergh AR, Janka-Schaub GE, Pieters R: Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood; 2005 Sep 1;106(5):1817-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia.
  • Drug resistance in childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) is associated with impaired ability to induce apoptosis.
  • To elucidate causes of apoptotic defects, we studied the protein expression of Apaf-1, procaspases-2, -3, -6, -7, -8, -10, and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) in cells from children with acute lymphoblastic leukemia (ALL; n = 43) and acute myeloid leukemia (AML; n = 10).
  • In conclusion, low baseline expression of PARP and procaspase-2 is related to cellular drug resistance in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Caspases / metabolism. Drug Resistance, Neoplasm / physiology. Poly(ADP-ribose) Polymerases / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Apoptosis / physiology. Caspase 2. Cell Line, Tumor. Child. Drug Screening Assays, Antitumor. Gene Expression Regulation, Enzymologic. Humans. RNA, Messenger / genetics. RNA, Messenger / physiology


28. Choi ER, Ko YH, Kim SJ, Jang JH, Kim K, Kang WK, Jung CW, Kim DH: Gastric recurrence of extramedullary granulocytic sarcoma after allogeneic stem cell transplantation for acute myeloid leukemia. J Clin Oncol; 2010 Feb 1;28(4):e54-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric recurrence of extramedullary granulocytic sarcoma after allogeneic stem cell transplantation for acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myelomonocytic, Acute / therapy. Neoplasm Recurrence, Local / etiology. Sarcoma, Myeloid / etiology. Stem Cell Transplantation. Stomach Neoplasms / etiology


29. Liu HT, Li Q, Guo X: [Clinical, morphologic immunologic and cytogenetic characteristics of childhood acute lymphoblastic leukemia: a comparison between prednisone poor responders and good responders]. Zhonghua Er Ke Za Zhi; 2007 Nov;45(11):865-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical, morphologic immunologic and cytogenetic characteristics of childhood acute lymphoblastic leukemia: a comparison between prednisone poor responders and good responders].
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prednisone / pharmacology


30. Kim DY, Choi SJ, Kim SH, Chung HY, Yi S, Kim DW, Kim CC, Han TH: Upregulated hoxC4 induces CD14 expression during the differentiation of acute promyelocytic leukemia cells. Leuk Lymphoma; 2005 Jul;46(7):1061-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulated hoxC4 induces CD14 expression during the differentiation of acute promyelocytic leukemia cells.
  • Acute promyelocytic leukemia (APL) cells carrying the PML-RARa fusion protein, respond well by differentiating in their response to an all-trans-retinoic acid (ATRA) treatment.
  • To further examine this finding, HoxC4 was stably expressed in NB4 cells by retroviral transduction.
  • The NB4 cells expressing HoxC4 showed differentiated phenotypes including a CD14 expression, which strongly suggests that upregulated hoxC4 is functionally involved in NB4 cell differentiation in response to ATRA.
  • Upregulation of CD14 is at the transcription level and mediated by the homeodomain of the HoxC4.
  • [MeSH-major] Antigens, CD14 / genetics. Cell Differentiation. Gene Expression Regulation, Leukemic. Homeodomain Proteins / metabolism. Leukemia, Promyelocytic, Acute / pathology

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019559.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Antineoplastic Agents; 0 / HOXC4 protein, human; 0 / Homeodomain Proteins; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin
  •  go-up   go-down


31. Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broët P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah N, Witz F, Dreyfus F, Mayeux P, Lacombe C, Bouscary D: Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood; 2007 Aug 1;110(3):1025-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.
  • The phosphoinositide 3-kinase (PI3K/Akt) pathway is activated in acute myelogenous leukemia (AML) and is promising for targeted inhibition.
  • No difference was observed between PI3K (+) and PI3K (-) groups concerning age, sex, white blood cell count, lactate dehydrogenase (LDH) level, bone marrow blast cells, French-American-British (FAB) classification, cytogenetics, RAS or nucleophosmin (NPM) mutations.
  • [MeSH-major] Blast Crisis / enzymology. Leukemia, Myeloid, Acute / enzymology. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Bone Marrow / enzymology. Bone Marrow / pathology. Disease-Free Survival. Enzyme Activation / genetics. Female. Humans. L-Lactate Dehydrogenase / genetics. L-Lactate Dehydrogenase / metabolism. Leukocyte Count. Male. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Survival Rate. fms-Like Tyrosine Kinase 3 / genetics. fms-Like Tyrosine Kinase 3 / metabolism. ras Proteins / genetics. ras Proteins / metabolism


32. Imataki O, Kamioka T, Fukuda T, Tanosaki R, Takaue Y: Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Support Care Cancer; 2010 Dec;18(12):1565-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.
  • GOALS OF WORK: Allogeneic stem cell transplantation with a reduced-intensity regimen (RIST) has been evaluated mostly in terms of its clinical benefit, and the pharmacoeconomic aspects of this procedure remain unclear.
  • We compared the cost and effectiveness of RIST with those of stem cell transplantation using a conventional myeloablative regimen (CST).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / economics. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / surgery
  • [MeSH-minor] Adult. Cost-Benefit Analysis. Female. Humans. Length of Stay / economics. Male. Middle Aged. Multivariate Analysis. Outcome and Process Assessment (Health Care). Quality-Adjusted Life Years. Retrospective Studies. Survival Analysis. Tokyo. Transplantation Conditioning / economics. Transplantation Conditioning / methods


33. Marchese VG, Connolly BH, Able C, Booten AR, Bowen P, Porter BM, Rai SN, Hancock ML, Pui CH, Howard S, Neel MD, Kaste SC: Relationships among severity of osteonecrosis, pain, range of motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia. Phys Ther; 2008 Mar;88(3):341-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationships among severity of osteonecrosis, pain, range of motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia.
  • BACKGROUND AND PURPOSE: Up to 38% of children receiving treatment for acute lymphoblastic leukemia (ALL) develop osteonecrosis, often without symptoms.
  • [MeSH-major] Arthralgia / physiopathology. Osteonecrosis / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Range of Motion, Articular / physiology. Severity of Illness Index

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202079.001).
  • [ISSN] 0031-9023
  • [Journal-full-title] Physical therapy
  • [ISO-abbreviation] Phys Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2U54CA055727-12; United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids
  •  go-up   go-down


34. Wattanawaraporn R, Singhsilarak T, Nuchprayoon I, Mutirangura A: Hypermethylation of TTC12 gene in acute lymphoblastic leukemia. Leukemia; 2007 Nov;21(11):2370-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of TTC12 gene in acute lymphoblastic leukemia.
  • [MeSH-major] DNA Methylation. Gene Expression Regulation, Leukemic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proteins / genetics
  • [MeSH-minor] Bone Marrow Cells / metabolism. Cell Line, Tumor. Cloning, Molecular. HeLa Cells. Humans. K562 Cells. Leukocytes, Mononuclear / metabolism. Neutrophils / metabolism. Remission Induction. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657212.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteins; 0 / TTC12 protein, human
  •  go-up   go-down


35. Taketani T, Taki T, Sako M, Ishii T, Yamaguchi S, Hayashi Y: MNX1-ETV6 fusion gene in an acute megakaryoblastic leukemia and expression of the MNX1 gene in leukemia and normal B cell lines. Cancer Genet Cytogenet; 2008 Oct 15;186(2):115-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MNX1-ETV6 fusion gene in an acute megakaryoblastic leukemia and expression of the MNX1 gene in leukemia and normal B cell lines.
  • Patients with infant acute myeloid leukemia (AML) who carry a t(7;12)(q36;p13) translocation have been reported to have a poor clinical outcome.
  • A 23-month-old girl with acute megakaryoblastic leukemia (AMKL) exhibited chromosome abnormalities, including add(7)(q22), and del(12)(p12p13).
  • The MNX1 expression by RT-PCR was significantly more frequent in Epstein-Barr virus-transformed B-cell lines derived from normal adult lymphocytes than in leukemic cell lines.
  • [MeSH-major] B-Lymphocytes / metabolism. Gene Fusion. Homeodomain Proteins / genetics. Leukemia / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Cell Line, Tumor. Chromosome Aberrations. Female. Humans. Infant. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18940475.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ETS translocation variant 6 protein; 0 / Homeodomain Proteins; 0 / MNX1 protein, human; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; 0 / Transcription Factors
  •  go-up   go-down


36. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP: Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma; 2010 Jan;51(1):73-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
  • Cytarabine resistance characterizes relapsed and refractory acute myelogenous leukemia (AML).
  • We conducted an adaptively randomized study of a combination of azacitidine, a hypomethylating agent, and cytarabine in 34 patients with AML.
  • However, in this advanced AML population, it was difficult to deliver more than one cycle of therapy, and minimal anti-leukemia activity was seen in patients with relapsed/refractory disease.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Dec 1;96(12):3671-4 [11090046.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7512-23 [14576855.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1635-40 [14604977.001]
  • [Cites] Biochim Biophys Acta. 1965 Nov 8;108(3):516-8 [5867538.001]
  • [Cites] Nat New Biol. 1971 Sep 22;233(38):109-10 [5285962.001]
  • [Cites] Cancer Res. 1974 Oct;34(10):2482-8 [4137739.001]
  • [Cites] Biochemistry. 1975 Jan 28;14(2):316-26 [47243.001]
  • [Cites] Oncology. 1974;30(5):405-22 [4142650.001]
  • [Cites] Cancer Res. 1975 Oct;35(10):2853-7 [50882.001]
  • [Cites] Cancer Res. 1976 Mar;36(3):1114-20 [56229.001]
  • [Cites] Cancer Res. 1978 Aug;38(8):2458-66 [78761.001]
  • [Cites] Cell. 1980 May;20(1):85-93 [6156004.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):4000-6 [6162541.001]
  • [Cites] Science. 1981 Jan 23;211(4480):393-6 [6164095.001]
  • [Cites] J Biol Chem. 1982 Feb 25;257(4):2041-8 [6173384.001]
  • [Cites] Cancer Res. 1984 Nov;44(11):5029-37 [6091869.001]
  • [Cites] Adv Enzyme Regul. 1985;24:335-54 [2424284.001]
  • [Cites] Semin Oncol. 1987 Jun;14(2 Suppl 1):257-61 [3035720.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(4):203-10 [2473850.001]
  • [Cites] Blood. 1997 Jul 1;90(1):346-53 [9207471.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):1096-103 [9886326.001]
  • [Cites] Drug Resist Updat. 2004 Aug-Oct;7(4-5):267-78 [15533764.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3895-903 [16921040.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1370-7 [17283175.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1634-7 [17363514.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4225-32 [17634552.001]
  • [Cites] Biometrics. 2007 Jun;63(2):429-36 [17688495.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1366-73 [18523155.001]
  • [Cites] Blood. 2009 Jan 15;113(3):659-67 [18931345.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • (PMID = 20017599.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100632-05; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA100632-04; United States / NCI NIH HHS / CA / P50 CA100632-079004; United States / NCI NIH HHS / CA / CA100632-07S1; United States / NCI NIH HHS / CA / P50 CA100632-06S1; United States / NCI NIH HHS / CA / P50 CA100632; United States / NCI NIH HHS / CA / P50 CA100632-069004; United States / NCI NIH HHS / CA / CA100632-04; United States / NCI NIH HHS / CA / CA100632-070006; United States / NCI NIH HHS / CA / CA100632-070001; United States / NCI NIH HHS / CA / CA100632-03; None / None / / P50 CA100632-06; United States / NCI NIH HHS / CA / CA100632-060001; United States / NCI NIH HHS / CA / P50 CA100632-03; United States / NCI NIH HHS / CA / P50 CA100632-06; United States / NCI NIH HHS / CA / CA100632-069004; United States / NCI NIH HHS / CA / P50 CA100632-070001; United States / NCI NIH HHS / CA / CA100632-06S1; United States / NCI NIH HHS / CA / P50 CA100632-010007; United States / NCI NIH HHS / CA / P50 CA100632-070006; None / None / / P50 CA100632-010007; United States / NCI NIH HHS / CA / CA100632; United States / NCI NIH HHS / CA / CA100632-079004; United States / NCI NIH HHS / CA / P50 CA100632-060001; United States / NCI NIH HHS / CA / P50 CA100632-07; United States / NCI NIH HHS / CA / P50 CA100632-060006; United States / NCI NIH HHS / CA / P50 CA100632-05; United States / NCI NIH HHS / CA / CA100632-060006; United States / NCI NIH HHS / CA / P50 CA100632-010001; United States / NCI NIH HHS / CA / P50 CA100632-07S1; United States / NCI NIH HHS / CA / CA100632-07; United States / NCI NIH HHS / CA / CA100632-010001
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ NIHMS200831; NLM/ PMC2876330
  •  go-up   go-down


37. Haimi M, Avivi I, Moustafa N, Aboleil O, Gershoni-Baruch R: Treatment-related acute myeloid leukemia characterized by t(11;20)(p15;q11) and del(9)(q22). Cancer Genet Cytogenet; 2006 Jun;167(2):186-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related acute myeloid leukemia characterized by t(11;20)(p15;q11) and del(9)(q22).
  • [MeSH-major] Chromosome Deletion. Leukemia, Monocytic, Acute / chemically induced. Leukemia, Monocytic, Acute / diagnosis. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / diagnosis. Translocation, Genetic
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 11 / ultrastructure. Chromosomes, Human, Pair 20 / ultrastructure. Chromosomes, Human, Pair 9 / ultrastructure. Female. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Genet Cytogenet. 2006 Aug;169(1):87. Motti, Haimi [corrected to Haimi, Motti]; Irit, Avivi [corrected to Avivi, Irit]; Nivin, Moustafa [corrected to Moustafa, Nivin]; Olfat, Aboleil [corrected to Aboleil, Olfat]; Ruth, Gershoni-Baruch [corrected to Gershoni-Baruch, Ruth]
  • (PMID = 16737924.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


38. Nagel S, Scherr M, Kel A, Hornischer K, Crawford GE, Kaufmann M, Meyer C, Drexler HG, MacLeod RA: Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1. Cancer Res; 2007 Feb 15;67(4):1461-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1.
  • In T-cell acute lymphoblastic leukemia, alternative t(5;14)(q35;q32.2) forms effect dysregulation of either TLX3 or NKX2-5 homeobox genes at 5q35 by juxtaposition with 14q32.2 breakpoints dispersed across the BCL11B downstream genomic desert.
  • Leukemic gene dysregulation by t(5;14) was investigated by DNA inhibitory treatments with 26-mer double-stranded DNA oligonucleotides directed against candidate enhancers at, or near, orphan T-cell DNase I hypersensitive sites located between 3'-BCL11B and VRK1.
  • We suggest that HMGA1 and PU.1 coregulate ectopic homeobox gene expression in t(5;14) T-cell acute lymphoblastic leukemia by interactions mediated at the nuclear matrix.
  • [MeSH-major] DNA-Binding Proteins / genetics. Gene Expression Regulation, Leukemic. HMGA Proteins / genetics. Homeodomain Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Oncogene Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / genetics. Repressor Proteins / genetics. Trans-Activators / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308084.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL11B protein, human; 0 / DNA-Binding Proteins; 0 / HMGA Proteins; 0 / Histones; 0 / Homeodomain Proteins; 0 / NKX2-5 protein, human; 0 / Oligonucleotides; 0 / Oncogene Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / Repressor Proteins; 0 / TLX3 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / proto-oncogene protein Spi-1; EC 3.1.21.1 / Deoxyribonuclease I
  •  go-up   go-down


39. Kato M, Kikuchi A, Oshima K, Yamamoto S, Mochizuki S, Arai K, Hanada R: [Pediatric acute lymphoblastic leukemia initially presenting with bone marrow necrosis]. Rinsho Ketsueki; 2007 Feb;48(2):140-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pediatric acute lymphoblastic leukemia initially presenting with bone marrow necrosis].
  • We report on a case of pediatric acute lymphoblastic leukemia presenting with massive bone marrow necrosis.
  • [MeSH-major] Bone Marrow / pathology. Bone Marrow Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis


40. Huang J, Ni W, Wang L, Zhou W, Jin J: A rare case of co-existent aggressive natural killer cell and acute monocytic leukemia with cytomegalovirus infection. Int J Hematol; 2008 Jun;87(5):553-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of co-existent aggressive natural killer cell and acute monocytic leukemia with cytomegalovirus infection.
  • [MeSH-major] Cytomegalovirus Infections / immunology. Killer Cells, Natural / immunology. Leukemia, Monocytic, Acute / immunology

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Jun 15;97(12):3902-9 [11389033.001]
  • [Cites] Blood. 1999 Jan 1;93(1):96-106 [9864151.001]
  • [Cites] Bone Marrow Transplant. 1997 Mar;19(5):471-80 [9052914.001]
  • [Cites] Br J Haematol. 1990 May;75(1):49-59 [2375924.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):621-5 [9207410.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 15;417(2):141-52 [12941295.001]
  • [Cites] Leuk Res. 2007 Jan;31(1):117-9 [16631250.001]
  • [Cites] Int J Hematol. 2007 Jan;85(1):18-25 [17261497.001]
  • [Cites] Exp Hematol. 1997 Nov;25(12):1278-85 [9357972.001]
  • [Cites] Leukemia. 2004 Apr;18(4):763-70 [14961041.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2186-94 [16179910.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1361-7 [16791270.001]
  • [Cites] Br J Haematol. 1995 Jul;90(3):578-84 [7646997.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4883-98 [9671497.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1101-4 [15718471.001]
  • [Cites] Eur J Haematol. 2006 Jan;76(1):86-8 [16343277.001]
  • (PMID = 18437504.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; ZS7284E0ZP / Daunorubicin; CROP protocol
  •  go-up   go-down


41. Maule MM, Merletti F, Pastore G, Magnani C, Richiardi L: Effects of maternal age and cohort of birth on incidence time trends of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev; 2007 Feb;16(2):347-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of maternal age and cohort of birth on incidence time trends of childhood acute lymphoblastic leukemia.
  • Several studies report increasing trends in the incidence of childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301270.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Anensen N, Øyan AM, Huseby S, Kalland KH, Bruserud Ø, Gjertsen BT: Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Rev Anticancer Ther; 2007 May;7(5):741-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early gene expression of acute myeloid leukemia in response to chemotherapy.
  • Such variation in gene expression may be the cause of different disease outcome and may reflect disease phenotypes or chemoresistance.
  • Acute myeloid leukemia is a malignant disease of the bone marrow where overall long-term disease-free survival is less than 50%.
  • The need for better disease classification and evaluation is consequently evident.
  • Gene expression profiling in acute myeloid leukemia has, in recent years, proven able to distinguish acute myeloid leukemia subclasses and predict clinical outcome and is, as such, a promising technique for improved disease evaluation.
  • The early detection of gene expression in response to chemotherapy may be a novel way of monitoring disease management.
  • The immediate gene response may be an indication of whether the drug of choice is efficient in leukemic cell eradication and may early indicate the need for other therapeutic measures.
  • Furthermore, these early alterations in gene expression could facilitate identification of new treatment targets, thereby enabling better patient care and follow-up in the future.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Monitoring / methods. Gene Expression / drug effects. Gene Expression Profiling. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Tumor Suppressor Protein p53 / drug effects

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17492937.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 80
  •  go-up   go-down


43. Inaba H, Jones DP, Gaber LW, Shenep JL, Call SK, Pui CH, Razzouk BI: BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia. J Pediatr; 2007 Aug;151(2):215-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia.
  • We report a case of BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurovirol. 1996 Dec;2(6):411-6 [8972423.001]
  • [Cites] Lancet. 1971 Jun 19;1(7712):1253-7 [4104714.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):527-30 [12181409.001]
  • [Cites] J Gen Virol. 2000 Aug;81(Pt 8):1967-73 [10900035.001]
  • [Cites] Transplantation. 2006 Jan 15;81(1):117-20 [16421486.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Clin Infect Dis. 2005 Aug 1;41(3):354-60 [16007533.001]
  • [Cites] Am J Transplant. 2005 Aug;5(8):1997-2004 [15996251.001]
  • [Cites] Pediatr Nephrol. 2005 Jun;20(6):782-5 [15782299.001]
  • [Cites] Leukemia. 1998 Apr;12(4):619-22 [9557622.001]
  • [Cites] Clin Infect Dis. 2005 Feb 15;40(4):528-37 [15712075.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1157-8 [15784677.001]
  • (PMID = 17643782.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-29; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-29
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Other-IDs] NLM/ NIHMS28072; NLM/ PMC2077844
  •  go-up   go-down


44. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J: Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies. Acta Paediatr; 2006 Jun;95(6):701-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies.
  • AIM: To investigate the possible relationship between serum levels and avidities of antibodies against tetanus toxoid (TT) and Haemophilus influenzae type b (Hib) in children that were vaccinated after treatment for childhood acute lymphoblastic leukaemia (ALL).
  • RESULTS: There was a correlation between level and avidity of tetanus antibodies after vaccination (r(s) = 0.59, P < 0.001).
  • [MeSH-major] Antibodies, Bacterial / immunology. Antibody Affinity. Haemophilus Vaccines / immunology. Haemophilus influenzae / immunology. Polysaccharides, Bacterial / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Tetanus Toxoid / immunology

  • Genetic Alliance. consumer health - Tetanus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754551.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Haemophilus Vaccines; 0 / Haemophilus influenzae type b polysaccharide vaccine; 0 / Polysaccharides, Bacterial; 0 / Tetanus Toxoid
  •  go-up   go-down


45. Chang WR, Park IJ, Lee HW, Park JS, Kim HC, Kim HJ, Han JH, Cho SR: [Two cases of acute myeloid leukemia with t(16;21)(p11;q22) and TLS/FUS-ERG fusion transcripts]. Korean J Lab Med; 2009 Oct;29(5):390-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of acute myeloid leukemia with t(16;21)(p11;q22) and TLS/FUS-ERG fusion transcripts].
  • One patient was a 24 yr-old male with acute myelomonocytic leukemia.
  • Although he received allogeneic peripheral blood stem cell transplantation after the first remission, he died 9 months after the initial diagnosis due to relapse of the disease and graft-versus-host disease.
  • The other patient was a 72 yr-old male with acute myeloid leukemia without maturation.
  • [MeSH-major] Chromosomes, Human, Pair 16 / genetics. Chromosomes, Human, Pair 22 / genetics. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. RNA-Binding Protein FUS / genetics. Translocation, Genetic
  • [MeSH-minor] Aged. Graft vs Host Disease / diagnosis. Humans. Karyotyping. Male. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893346.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA-Binding Protein FUS; 0 / TLS-ERG fusion protein, human
  •  go-up   go-down


46. Prebet T, Lhoumeau AC, Arnoulet C, Aulas A, Marchetto S, Audebert S, Puppo F, Chabannon C, Sainty D, Santoni MJ, Sebbagh M, Summerour V, Huon Y, Shin WS, Lee ST, Esterni B, Vey N, Borg JP: The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. Blood; 2010 Sep 30;116(13):2315-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome.
  • The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway.
  • We demonstrated that PTK7 is expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation.
  • Patients with PTK7-positive AML are more resistant to anthracycline-based frontline therapy with a significantly reduced leukemia-free survival in a multivariate analysis model.
  • In vitro, expression of PTK7 in cultured leukemia cells promotes cell migration, cell survival, and resistance to anthracycline-induced apoptosis.
  • Furthermore, we efficiently sensitized primary AML blasts to anthracycline-mediated cell death using a recombinant soluble PTK7-Fc protein.
  • We conclude that PTK7 is a planar cell polarity component expressed in the myeloid progenitor compartment that conveys promigratory and antiapoptotic signals into the cell and that represents an independent prognosis factor of survival in patients treated with induction chemotherapy.
  • [MeSH-major] Cell Adhesion Molecules / metabolism. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / metabolism. Receptor Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Anthracyclines / pharmacology. Antibiotics, Antineoplastic / pharmacology. Apoptosis. Base Sequence. Cell Line, Tumor. Cell Movement. Cell Polarity. Cytogenetic Analysis. DNA Primers / genetics. Drug Resistance, Neoplasm. HL-60 Cells. Humans. Immunophenotyping. In Vitro Techniques. Jurkat Cells. K562 Cells. Prognosis. Treatment Outcome. U937 Cells

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20558616.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Cell Adhesion Molecules; 0 / DNA Primers; EC 2.7.1.- / PTK7 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


47. Kamble RT, Hjortsvang E, Selby GB: Leukemia burden and outcome of allogeneic transplant in acute myelogenous leukemia. Biol Blood Marrow Transplant; 2006 Jun;12(6):691-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia burden and outcome of allogeneic transplant in acute myelogenous leukemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Humans. Leukemia, Myeloid. Transplantation, Homologous. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Biol Blood Marrow Transplant. 2006 Jan;12(1):61-7 [16399569.001]
  • (PMID = 16737944.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


48. Meshinchi S, Appelbaum FR: Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res; 2009 Jul 1;15(13):4263-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural and functional alterations of FLT3 in acute myeloid leukemia.
  • Ligand-induced stimulation of the FMS-like tyrosine kinase 3 (FLT3) leads to activation of multiple downstream effector pathways resulting in differentiation and proliferation of specific progenitor cell populations.
  • Exploring the mechanisms by which these FLT3 alterations lead to dysregulated proliferation should provide a better understanding of the molecular pathogenesis of acute myeloid leukemia (AML) and may provide insights into potential therapeutic interventions.


49. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood; 2008 Feb 15;111(4):1827-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
  • An international collaboration was set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphoblastic leukemia (ALL) and compare autologous transplantation with standard chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Humans. Middle Aged. Recurrence. Risk Factors. Siblings. Survival Analysis. Transplantation, Autologous. Transplantation, Homologous


50. Gutierrez-Aguirre CH, Cantú-Rodríguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-González O, Jaime-Pérez JC, Morales-Toquero A, Tarín-Arzaga LC, Ruiz-Argüelles GJ, Gómez-Almaguer D: Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology; 2007 Jun;12(3):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective strategy for preventing relapse of acute myelogenous leukemia (AML).
  • All patients received cyclosporine-A (CsA) and methotrexate as graft vs. host disease (GvHD) prophylaxis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclosporine / administration & dosage. Graft Survival. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Humans. Mexico. Middle Aged. Recurrence. Salvage Therapy / methods. Transplantation Conditioning / methods. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558694.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


51. Bain BJ: Hemophagocytosis evolving into acute lymphoblastic leukemia. Am J Hematol; 2005 Mar;78(3):246-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemophagocytosis evolving into acute lymphoblastic leukemia.
  • [MeSH-major] Histiocytosis, Non-Langerhans-Cell / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Hematol. 2004 Aug;76(4):364-7 [15282670.001]
  • (PMID = 15726603.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


52. Karrman K, Andersson A, Björgvinsdóttir H, Strömbeck B, Lassen C, Olofsson T, Nguyen-Khac F, Berger R, Bernard O, Fioretos T, Johansson B: Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia. Eur J Haematol; 2006 Jul;77(1):27-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia.
  • OBJECTIVES: The t(12;14)(p13;q11)--a recurrent translocation in childhood T-cell acute lymphoblastic leukemia (T-ALL)--has very recently been molecularly characterized in one case, which displayed overexpression of the cyclin D2 gene (CCND2).
  • RESULTS: FISH revealed breakpoints (BPs) in the T-cell receptor alpha/delta locus (14q11) and in the vicinity of the CCND2 gene at 12p13.
  • Neither PARP11 nor FGF23 displayed expression differences among the T-ALLs, whereas CCND2 was clearly overexpressed in both t(12;14)-positive cases as compared to the mean expression level in the controls.
  • Furthermore, it is the first example of a T-cell neoplasm with a targeted deregulation of a member of a cyclin-encoding gene family.
  • [MeSH-major] Cyclins / genetics. Gene Expression Regulation, Neoplastic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, gamma-delta / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548914.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


53. Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland MC, Heinecke A, Berning B, Scheffold C, Silling G, Buchner T, Neubauer A, Fauser AA, Ehninger G, Berdel WE, Kienast J, Cooperative German Transplant Study Group: Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood; 2005 Nov 1;106(9):3314-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
  • Seventy-one patients with acute myeloid leukemia (AML), most of them (63/71) considered ineligible for conventional allogeneic hematopoietic stem cell transplantation (HSCT), were enrolled into a phase 2 study on reduced-intensity myeloablative conditioning with fractionated 8-Gy total body irradiation (TBI) and fludarabine (120 mg/m2).
  • Thirty-six patients received a transplant in complete remission (CR) and 35 had untreated or refractory disease (non-CR).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / radiotherapy. Transplantation Conditioning / methods. Vidarabine / analogs & derivatives. Whole-Body Irradiation
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome


54. Wang L, Zhang LP, Li ZG, Cheng YF, Tian KG, Lu AD: [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2005 Mar;43(3):170-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
  • OBJECTIVE: Hematologic relapse remains the greatest obstacle to the cure of acute lymphoblastic leukemia (ALL), especially T-lineage acute lymphoblastic leukemia (T-ALL) in children.
  • Recent studies have shown that patients with increased risk of relapse can be identified by measuring residual leukemic cells, called minimal residual disease (MRD), during clinical remission.
  • (2) The RQ-PCR assay had a sensitivity of detection of one leukemic cell among 100,000 normal cells.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / genetics. Gene Deletion. Polymerase Chain Reaction / methods. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15833185.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Proto-Oncogene Proteins; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


55. Chan MS, Roebuck DJ, Yuen MP, Li CK, Chan YL: MR imaging of the brain in patients cured of acute lymphoblastic leukemia--the value of gradient echo imaging. AJNR Am J Neuroradiol; 2006 Mar;27(3):548-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of the brain in patients cured of acute lymphoblastic leukemia--the value of gradient echo imaging.
  • BACKGROUND AND PURPOSE: Hemosiderin and white matter lesions are 2 of the most common neurologic complications found on MR imaging that may be related to cranial irradiation and intrathecal methotrexate (MTX) therapy in childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Brain / pathology. Magnetic Resonance Imaging. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551991.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


56. Seror E, DeVillartay P, Leverger G, Lenoir G: [HHV-6 infection and acute lymphoblastic leukemia in a child]. Arch Pediatr; 2008 Jan;15(1):37-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HHV-6 infection and acute lymphoblastic leukemia in a child].
  • We report the case of a child who was infected by HHV-6 and who started an acute lymphoblastic leukemia two months later.
  • This case reminds that an etiologic role have been suggested for many viral infections in some leukemias in childhood, particularly the human herpesvirus 6 (HHV-6).
  • [MeSH-major] Herpesvirus 6, Human. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Roseolovirus Infections / complications
  • [MeSH-minor] Blast Crisis. Blood Cell Count. Child, Preschool. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162384.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


57. Cory JG, Cory AH: Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia. In Vivo; 2006 Sep-Oct;20(5):587-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia.
  • Asparaginase is a key component of the chemotherapy protocols used in the treatment of acute lymphoblastic leukemia (ALL).
  • Glutamine is a required substrate for three enzymes involved in the de novo synthesis of purine nucleotides and two enzymes involved in the de novo synthesis of pyrimidine nucleotides.
  • In this review, the specific roles of glutamine in the de novo synthesis of nucleotides are defined and an appropriate explanation for the cell cycle arrest and cytotoxicity induced in proliferating malignant lymphoblasts by asparaginase treatment is provided.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Asparaginase / therapeutic use. Glutamine / chemistry. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Purine Nucleotides / biosynthesis. Pyrimidine Nucleotides / biosynthesis
  • [MeSH-minor] Cell Cycle. Molecular Structure. Nitrogen / chemistry

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091764.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Purine Nucleotides; 0 / Pyrimidine Nucleotides; 0RH81L854J / Glutamine; EC 3.5.1.1 / Asparaginase; N762921K75 / Nitrogen
  • [Number-of-references] 7
  •  go-up   go-down


58. Fu MW, Mi YC, Qiu LG, Yu WJ, Lin D, Bian SG, Wang JX: [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jul;29(7):435-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia].
  • OBJECTIVE: To explore the clinical characteristics of adult acute lymphoblastic leukemia (ALL), compare the efficacy of different induction regimens and analyze the prognostic factors.
  • With a median follow-up of 14.5 (1-75) months, the median disease free survival (DFS) was 12 (1-74) months and median overall survival (OS) 17.5 (1-97) months.
  • 3) COX regression analysis showed that the age (over 40 years), white blood cell (WBC) count ( > 40 x 10(9)/L) , t(9;22) (q34;q11)-positive and less than 4 courses consolidation chemotherapy were the unfavorable prognostic factors.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035173.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


59. Harrison CJ, Griffiths M, Moorman F, Schnittger S, Cayuela JM, Shurtleff S, Gottardi E, Mitterbauer G, Colomer D, Delabesse E, Castéras V, Maroc N: A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. Cancer Genet Cytogenet; 2007 Feb;173(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device.
  • Rearrangements of the MLL gene are significant in acute leukemia.
  • Among the most frequent translocations are t(4;11)(q21;q23) and t(9;11)(p22;q23), which give rise to the MLL-AFF1 and MLL-MLLT3 fusion genes (alias MLL-AF4 and MLL-AF9) in acute lymphoblastic and acute myeloid leukemia, respectively.
  • Current evidence suggests that determining the MLL status of acute leukemia, including precise identification of the partner gene, is important in defining appropriate treatment.
  • A novel molecular diagnostic device, the MLL FusionChip, has been successfully used to identify MLL fusion gene translocations in acute leukemia, including the precise breakpoint location.
  • The type of molecular information provided by MLL FusionChip gave an indication of the appropriate primers to design for disease monitoring of MLL patients following treatment.
  • [MeSH-major] Leukemia, Myeloid / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adult. Child. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Chromosomes, Human, Pair 9. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Infant. Oligonucleotide Array Sequence Analysis / instrumentation. Oligonucleotide Array Sequence Analysis / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Genet Cytogenet. 2007 Dec;179(2):167
  • (PMID = 17284365.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / MLL-AF4 fusion protein, human; 0 / MLL-AF9 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Neoplasm; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


60. Vaudre G, Parker JL, Leverger G: [Living after an acute lymphoblastic leukemia]. Soins Pediatr Pueric; 2006 Jun;(230):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Living after an acute lymphoblastic leukemia].
  • [MeSH-major] Adaptation, Psychological. Adolescent, Hospitalized / psychology. Attitude to Health. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Psychology, Adolescent


61. Parkin B, Ouillette P, Wang Y, Liu Y, Wright W, Roulston D, Purkayastha A, Dressel A, Karp J, Bockenstedt P, Al-Zoubi A, Talpaz M, Kujawski L, Liu Y, Shedden K, Shakhan S, Li C, Erba H, Malek SN: NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res; 2010 Aug 15;16(16):4135-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NF1 inactivation in adult acute myelogenous leukemia.
  • PURPOSE: This study was conducted to identify novel genes with importance to the biology of adult acute myelogenous leukemia (AML).
  • These NF1 mutations were already present in the hematopoetic stem cell compartment.
  • Subsequent expression analysis of NF1 mRNA in the entire AML cohort using fluorescence-activated cell sorting sorted blasts as a source of RNA identified six patients (one with a NF1 mutation) with absent NF1 expression.
  • CONCLUSIONS: NF1 null states are present in 7 of 95 (7%) of adult AML and delineate a disease subset that could be preferentially targeted by Ras or mammalian target of rapamycin-directed therapeutics.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1012-21 [18281475.001]
  • [Cites] N Engl J Med. 1997 Jun 12;336(24):1713-20 [9180088.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6708-13 [18458336.001]
  • [Cites] Leukemia. 2008 May;22(5):915-31 [18288131.001]
  • [Cites] Blood. 2008 Aug 1;112(3):814-21 [18490517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11921-6 [18697940.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1993-2003 [18436738.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4603-9 [18559876.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10349-57 [19074904.001]
  • [Cites] Cancer Cell. 2009 Jul 7;16(1):44-54 [19573811.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12950-5 [19651600.001]
  • [Cites] Clin Cancer Res. 2009 Nov 1;15(21):6732-9 [19843663.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):181-8 [10620616.001]
  • [Cites] Leukemia. 2000 Mar;14(3):513-7 [10720153.001]
  • [Cites] J Clin Invest. 2001 Sep;108(5):709-15 [11544276.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2003 Aug 1;102(3):972-80 [12702506.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] Blood. 1991 Mar 1;77(5):925-9 [1704804.001]
  • [Cites] Am J Clin Pathol. 1993 Nov;100(5):534-40 [8249893.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):597-601 [8302341.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):50874-85 [15371411.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2527-34 [15550488.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3217-24 [15867216.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8 [15937108.001]
  • [Cites] Biogerontology. 2005;6(3):185-92 [16041622.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):337-48 [16226708.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9152-4 [16230371.001]
  • [Cites] J Biol Chem. 2005 Nov 25;280(47):39524-33 [16169856.001]
  • [Cites] Leukemia. 2006 Apr;20(4):635-44 [16467864.001]
  • [Cites] Leukemia. 2006 May;20(5):840-6 [16498392.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3887-94 [16864856.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5165-73 [16951235.001]
  • [Cites] Cancer Cell. 2006 Sep;10(3):179-90 [16959610.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1224-31 [17377590.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4777-85 [17699855.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1534-42 [17954704.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1584-93 [17971485.001]
  • [Cites] Leukemia. 2008 Feb;22(2):240-8 [18200041.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4322-8 [18172006.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):137-43 [8563750.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):144-8 [8563751.001]
  • [CommentOn] Clin Cancer Res. 2010 Aug 15;16(16):4074-6 [20587590.001]
  • (PMID = 20505189.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA136537; United States / NCI NIH HHS / CA / 1R01 CA136537-01; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / R01 CA136537-02; United States / NCI NIH HHS / CA / CA136537-02
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS210184; NLM/ PMC2921448
  •  go-up   go-down


62. Charoensuk V, Gati WP, Weinfeld M, Le XC: Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells. Toxicol Appl Pharmacol; 2009 Aug 15;239(1):64-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells.
  • Arsenic trioxide, As(2)O(3), has successfully been used to treat acute promyelocytic leukemia (APL).
  • To further understand the cytotoxicity of arsenic compounds in APL cells, HL-60 cells were exposed to graded concentrations of the following arsenicals for up to 48 h: arsenic trioxide (As(III)), sodium arsenate (As(V)), phenylarsine oxide (PAO(III)), monomethylarsonous acid (MMA(III)), monomethylarsonic acid (MMA(V)) and dimethylarsinic acid (DMA(V)), and the viability and modes of cell death assessed.
  • The arsenic-exposed cells were stained with annexin V-PE and 7-aminoactinomycin D (7-AAD) and analyzed by flow cytometry in order to detect apoptotic and viable cells while cell morphology was visualized using scanning and transmission electron microscopy.
  • Acridine orange staining and microtubule-associated protein 1 light chain 3 (MAP-LC3) detection were used to recognize autophagic cell death.
  • [MeSH-minor] Caspase 3 / metabolism. Cell Survival / drug effects. Flow Cytometry. HL-60 Cells. Humans. Leukemia, Promyelocytic, Acute. Microscopy, Electron, Scanning. Microscopy, Electron, Transmission. Microtubule-Associated Proteins / metabolism. Structure-Activity Relationship

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465042.001).
  • [ISSN] 1096-0333
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Microtubule-Associated Proteins; 0 / light chain 3, human; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


63. Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R: Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia; 2008 Sep;22(9):1798-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Folic Acid / genetics. Methotrexate / adverse effects. Polymorphism, Genetic / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


64. Zeng DF, Kong PY, Chen XH, Wei L, Chang C, Peng XG: [The expression and clinical significance of stromal cell-derived factor-1 and CXCR4 in acute leukemia and malignant lymphoma]. Zhonghua Nei Ke Za Zhi; 2005 Jul;44(7):522-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression and clinical significance of stromal cell-derived factor-1 and CXCR4 in acute leukemia and malignant lymphoma].
  • OBJECTIVE: To analyze the expression of stromal cell derived factor-1 (SDF-1) and its functional chemokine receptor CXCR4 in patients with acute leukemia and malignant lymphoma.
  • The serum level of SDF-1 was determined with ELISA assay.
  • RESULTS: The expression of SDF-1 and CXCR4 in acute leukemia for ALL group, the expression of SDF-1 and CXCR4 is (7115.8 +/- 946.5) ng/L and (77.2 +/- 9.7)%; for ANLL group, the expression is (4642.2 +/- 1146.8) ng/L, (38.9 +/- 11.0)% and malignant lymphoma for HD group, the expression of SDF-1 and CXCR4 is (3728.9 +/- 690.9) ng/L and (9.2 +/- 2.7)%; for NHL group, the expression is (4442.1 +/- 1073.0) ng/L and (8.5 +/- 2.4)% patients were higher than that in controls the expression of SDF-1 and CXCR4 is (2369.3 +/- 966.5) ng/L and (2.7 +/- 1.5)% (P < 0.01).
  • In the leukemia group, the patients with extra-marrow infiltration have higher expression of SDF-1/CXCR4 than those without and the patients; in the lymphoma group.
  • CONCLUSIONS: The high expression of SDF-1 and CXCR4 is somewhat correlated with the pathogenetic process and infiltration characteristics of acute leukemia and malignant lymphoma.
  • [MeSH-major] Chemokines, CXC / blood. Leukemia, Myeloid, Acute / metabolism. Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Receptors, CXCR4 / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080846.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Receptors, CXCR4
  •  go-up   go-down


65. Seror E, Coquerel B, Gautheret-Dejean A, Ballerini P, Landman-Parker J, Leverger G, Schneider P, Vannier JP: Quantitation of Human herpes virus 6 genome in children with acute lymphoblastic leukemia. J Med Virol; 2008 Apr;80(4):689-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitation of Human herpes virus 6 genome in children with acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia is the main type of leukemia in children.
  • The potential role of HHV-6 in the pathogenesis of pediatric acute lymphoblastic leukemia was investigated.
  • HHV-6 genome copy number was measured by quantitative real-time PCR (RQ-PCR) in bone marrow or peripheral blood samples obtained from 36 children (median age = 4 years) with B acute lymphoblastic leukemia (n = 31) and T acute lymphoblastic leukemia (n = 5) at diagnosis and during complete remission.
  • A total of 24.7% of samples were positive for HHV-6 genome: 13.9% were leukemia samples and 34.1% were complete remission samples.
  • These results argue against a role of HHV6 infection in the development of pediatric acute lymphoblastic leukemia.
  • [MeSH-major] DNA, Viral / analysis. Herpesvirus 6, Human / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / virology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / virology. Roseolovirus Infections / complications. Roseolovirus Infections / virology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297709.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


66. Vijayakrishnan J, Sherborne AL, Sawangpanich R, Hongeng S, Houlston RS, Pakakasama S: Variation at 7p12.2 and 10q21.2 influences childhood acute lymphoblastic leukemia risk in the Thai population and may contribute to racial differences in leukemia incidence. Leuk Lymphoma; 2010 Oct;51(10):1870-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation at 7p12.2 and 10q21.2 influences childhood acute lymphoblastic leukemia risk in the Thai population and may contribute to racial differences in leukemia incidence.
  • Recent genome-wide association (GWA) studies of childhood acute lymphoblastic leukemia (ALL) have identified 7p12.2, 9p21.3, 10q21.2, and 14q11.2 SNPs that confer modest risks of ALL.
  • Consistent with findings in European populations, rs4132601 genotype was significantly associated with risk of ALL (odds ratio [OR] = 1.57, 95% confidence interval [CI]: 1.01-2.44; p = 0.04), and rs10821938 genotype was significantly associated with B-cell precursor ALL (OR = 0.73, 95% CI: 0.55-0.97; p = 0.03).
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 7 / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Asian Continental Ancestry Group / genetics. Case-Control Studies. Child. European Continental Ancestry Group / genetics. Female. Gene Frequency. Genetic Predisposition to Disease / genetics. Genotype. Humans. Incidence. Linkage Disequilibrium. Male. Risk Factors. Thailand / epidemiology. Young Adult


67. Cole PD, Drachtman RA, Masterson M, Smith AK, Glod J, Zebala JA, Lisi S, Drapala DA, Kamen BA: Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. Cancer Chemother Pharmacol; 2008 Jun;62(1):65-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768625.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI068282-01; United States / NIAID NIH HHS / AI / R43 AI068282; United States / NIAID NIH HHS / AI / R43 AI068282-01
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antidotes; 0 / Antimetabolites, Antineoplastic; 0 / Folic Acid Antagonists; JYB41CTM2Q / Aminopterin; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


68. Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, Manabe A, Saha V, Baruchel A, Vettenranta K, Horibe K, Benoit Y, Pieters R, Escherich G, Silverman LB, Pui CH, Valsecchi MG: Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol; 2010 Nov 1;28(31):4755-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.
  • PURPOSE: In a previous analysis of 326 children with Philadelphia chromosome (Ph) -positive acute lymphoblastic leukemia (ALL) treated between 1986 and 1996, hematopoietic stem-cell transplantation from HLA-matched related donors, but not from unrelated donors, offered a superior outcome than chemotherapy alone.
  • Transplantations with matched related donors and unrelated donors were equivalent and offered better disease control compared with chemotherapy alone.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2730-41 [9763557.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3110-8 [19059878.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5175-81 [19805687.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5168-74 [19805690.001]
  • [Cites] Leukemia. 2010 Feb;24(2):371-82 [20010620.001]
  • [Cites] Leukemia. 2010 Feb;24(2):406-18 [20010621.001]
  • [Cites] Leukemia. 2010 Feb;24(2):345-54 [20010622.001]
  • [Cites] Leukemia. 2010 Feb;24(2):265-84 [20010625.001]
  • [Cites] Leukemia. 2010 Feb;24(2):355-70 [20016527.001]
  • [Cites] Leukemia. 2010 Feb;24(2):309-19 [20016528.001]
  • [Cites] Leukemia. 2010 Feb;24(2):298-308 [20016530.001]
  • [Cites] Leukemia. 2010 Feb;24(2):285-97 [20016531.001]
  • [Cites] Leukemia. 2010 Feb;24(2):255-64 [20016536.001]
  • [Cites] Leukemia. 2010 Feb;24(2):320-34 [20016537.001]
  • [Cites] Leukemia. 2010 Feb;24(2):397-405 [20016538.001]
  • [Cites] Leukemia. 2010 Feb;24(2):335-44 [20016539.001]
  • [Cites] Leukemia. 2010 Feb;24(2):383-96 [20033052.001]
  • [Cites] Leukemia. 2010 Feb;24(2):253-4 [20145664.001]
  • [Cites] Blood. 2010 Apr 22;115(16):3206-14 [20154213.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Leukemia. 2004 Apr;18(4):693-702 [15044926.001]
  • [Cites] Klin Padiatr. 1987 May-Jun;199(3):151-60 [3306129.001]
  • [Cites] Blood. 1991 Jan 15;77(2):324-30 [1985699.001]
  • [Cites] Lancet. 1991 May 4;337(8749):1055-8 [1673492.001]
  • [Cites] Blood. 1991 Nov 1;78(9):2411-8 [1932753.001]
  • [Cites] Leukemia. 1996 Jun;10(6):957-63 [8667652.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] Stat Med. 2007 Oct 30;26(24):4505-19 [17348080.001]
  • (PMID = 20876426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA086011; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U24 CA114766
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / HLA Antigens; 0 / Protein Kinase Inhibitors
  • [Other-IDs] NLM/ PMC3020705
  •  go-up   go-down


69. Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, de Longueville F, Zintl F, Remacle J, Efferth T: ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res; 2006 Jul 15;12(14 Pt 1):4357-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia.
  • BACKGROUND: A major issue in the treatment of acute myeloid leukemia (AML) is resistance to chemotherapeutic drugs.
  • Incubation of cell lines with a number of different cytostatic drugs induced an up-regulation of ABCA3.
  • [MeSH-major] ATP-Binding Cassette Transporters / physiology. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics


70. Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kasai M, Fukuda T, Azuma H, Takanashi M, Okamoto S, Tsuchida M, Kawa K, Morishima Y, Kodera Y, Kato S, Japan Cord Blood Bank Network: Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood; 2009 Feb 19;113(8):1631-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia.
  • We made a disease-specific comparison of unrelated cord blood (CB) recipients and human leukocyte antigen allele-matched unrelated bone marrow (BM) recipients among 484 patients with acute myeloid leukemia (AML; 173 CB and 311 BM) and 336 patients with acute lymphoblastic leukemia (ALL; 114 CB and 222 BM) who received myeloablative transplantations.
  • In multivariate analyses, among AML cases, lower overall survival (hazard ratio [HR]=1.5; 95% confidence interval [CI], 1.0-2.0, P= .028) and leukemia-free survival (HR=1.5; 95% CI, 1.1-2.0, P= .012) were observed in CB recipients.
  • In ALL, there was no significant difference between the groups for relapse (HR=1.4, 95% CI, 0.8-2.4, P= .19) and treatment-related mortality (HR=1.0; 95% CI, 0.6-1.7, P= .98), which contributed to similar overall survival (HR=1.1; 95% CI, 0.7-1.6, P= .78) and leukemia-free survival (HR=1.2; 95% CI, 0.9-1.8, P= .28).
  • Matched or mismatched single-unit CB is a favorable alternative stem cell source for patients without a human leukocyte antigen-matched related or unrelated donor.
  • [MeSH-major] Bone Marrow Transplantation / mortality. Cord Blood Stem Cell Transplantation / mortality. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Platelets / cytology. Cause of Death. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease / epidemiology. Histocompatibility Testing. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Neutrophils / cytology. Recurrence. Risk Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104080.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Yoshida M; Sato K; Kohda K; Kobayashi N; Kobayashi R; Fukuhara T; Masauji N; Suzuki N; Ishida T; Matsunaga T; Imamura M; Kaneda M; Nishio M; Sasaki S; Ogura K; Ishida Y; Endo M; Okuda M; Kameoka J; Sasahara Y; Mitsui T; Tajima K; Fujishima N; Ogawa K; Kikuta A; Takayama N; Okamoto S; Shimada H; Waki A; Mori S; Hagiwara S; Kumagai M; Hamano Y; Yanagisawa K; Tashiro H; Fukuda T; Kajiwara M; Kimura Y; Yano S; Yoshinaga K; Takahashi S; Takita J; Akiyama H; Kaneko T; Ueno H; Tajika K; Suzuki K; Hatta Y; Chin M; Sakai R; Fujita H; Goto H; Kanamori H; Kigasawa H; Inoue Y; Onizuka M; Yabe H; Takeuchi M; Tanaka H; Okimoto Y; Yokota A; Nakaseko C; Ishiwada N; Katayama T; Kawai N; Watabe R; Maseki N; Kikuchi A; Ohshima K; Kimura F; Kogawa K; Koike K; Kamoshita M; Hasegawa Y; Muroi K; Sasaki K; Sugita K; Sakura T; Saito T; Kanazawa T; Sugita K; Asami K; cho T; Furukawa T; Koike T; Ito T; Yanagisawa R; Ishii E; Kobayashi H; Naito K; Yagyu T; Takashima Y; Ikeda T; Yago K; Taguchi J; Shigeno K; Okada S; Mihara H; Morishima Y; Morishita Y; Sawa M; Hamaguchi M; Kusumoto S; Murata M; Kojima S; Kato K; Miyamura K; Kasai M; Shimokawa T; Sao H; Kawakami K; Nakase K; Azuma E; Tamaki S; Oka K; Yoshida T; Kanegane H; Fukushima T; Nishimura R; Takami A; Ymaguchi M; Tanizawa A; Kasahara S; Kito K; Doi S; Ito M; Kuroda H; Ichinohe T; Adachi S; Nakagawa H; Taniwaki M; Hatanaka K; Kishimoto Y; Ashida T; Sakata N; Ishida H; Yonetani N; Hara J; Yamane T; Tsudo M; Maeda T; Ohta H; Hiraoka A; Inoue M; Akasaka H; Usami I; Nagai K; Okamura A; Hayakawa A; Otsuka Y; Okada M; Murayama T; Kosaka Y; Yagi H; Nakamura F; Amano I; Higuchi B; Sonoki T; Endo A; Ago H; Okazaki T; Ueyama J; Maeda Y; Sayama K; Ueda Y; Sunami K; Hamamoto K; Iwato K; Kobayashi M; Niimi H; Yujiri T; Ohnishi H; Abe M; Togitani K; Hara M; Tauchi H; Narumi H; Muta T; Yakushiji K; Matsuzaki A; Nagafuji K; Abe Y; Kamimura T; Eto T; Morimoto H; Miyaji R; Imada K; Imamura Y; Uike N; Nagatoshi Y; Moriuchi Y; Miyazaki Y; Otsuka E; Ogata M; Morinaga S; Hidaka M; Otsuka M; Takatsuka Y; Matsushita K; Okamoto Y; Okamura T; Tomoyose T; Kaneda M; Nishio M; Imamura M; Tanaka J; Kobayashi R; Kobayashi N; Suzuki N; Ishida T; Matsunaga T; Yoshida M; Sato K; Kohda K; Masauji N; Fukuhara T; Sasaki S; Ogura K; Endo M; Ishida Y; Sasahara Y; Kameoka J; Okuda M; Meguro K; Imaizumi M; Watanabe A; Fujishima N; Mitsui T; Tajima K; Kikuta A; Ogawa K; Kimura H; Koike K; Komatsu T; Hasegawa Y; Kamoshita M; Muroi K; Sugita K; Sasaki K; Kanazawa T; Saito T; Sakura T; Kikuchi A; Kimura F; Shibuya A; Kawai N; Maseki N; Hirabayashi K; Watabe R; Ohshima K; Nakaseko C; Ishiwada N; Okimoto Y; Aotsuka N; Tanaka H; Yokota A; Takeuchi M; Katayama T; Ishii A; Takita J; Okamoto S; Shimada H; Mori S; Chin M; Hatta Y; Yano S; Kajiwara M; Fukuda T; Takahashi S; Kaku H; Akiyama H; Kumagai M; Yoshinaga K; Ueno H; Ohara A; Tajika K; Tashiro H; Waki A; Hagiwara S; Kozai Y; Suzuki K; Kikuchi T; Yanagisawa K; Kaneko T; Kimura Y; Hamano Y; Manabe A; Usuki K; Takayama N; Miyakoshi S; Yabe H; Onizuka M; Goto H; Fujita H; Sakai R; Kigasawa H; Kanamori H; Isoyama K; Sano F; Inoue Y; Sugita K; Iino M; Yanagisawa R; Ito T; Ishii E; Kobayashi H; Asami K; cho T; Koike T; Furukawa T; Yoshida T; Kanegane H; Nishimura R; Takami A; Fukushima T; Ymaguchi M; Tanizawa A; Kasahara S; Takao A; Yago K; Takashima Y; Shigeno K; Okada S; Naito K; Taguchi J; Yagyu T; Ikeda T; Kato K; Miyamura K; Kasai M; Hamaguchi M; Murata M; Kojima S; Morishita Y; Sao H; Emi N; Morishima Y; Kusumoto S; Sawa M; Mihara H; Oka K; Tamaki S; Azuma E; Nakase K; Kawakami K; Taga T; Kito K; Kuroda H; Ito M; Nakagawa H; Adachi S; Ichinohe T; Taniwaki M; Doi S; Hiraoka A; Ohta H; Maeda T; Inoue M; Kishimoto Y; Hara J; Teshima H; Ashida T; Sakata N; Ishida H; Uoshima N; Kazumi Y; Yamane T; Hatanaka K; Yonetani N; Ishii K; Tsudo M; Tanaka H; Yamagami T; Arima N; Anzai N; Aoyama Y; Otsuka Y; Okada M; Murayama T; Hayakawa A; Okamura A; Matsushita A; Kosaka Y; Nagai K; Nakamura F; Higuchi B; Amano I; Sawada H; Yagi H; Sonoki T; Nougawa M; Nakahashi T; Ago H; Ueyama J; Okazaki T; Sayama K; Maeda Y; Ueda Y; Imajo K; Sunami K; Wada H; Hamamoto K; Iwato K; Kobayashi M; Hyodo H; Niimi H; Yujiri T; Abe M; Goto T; Ohnishi H; Imai T; Hara M; Muta T; Narumi H; Kaneko M; Togitani K; Matsuzaki A; Nagafuji K; Abe Y; Nagatoshi Y; Uike N; Imamura Y; Eto T; Morimoto H; Miyaji R; Imada K; Okamura S; Yakushiji K; Kamimura T; Takamatsu Y; Ohno Y; Sueoka E; Miyazaki Y; Moriuchi Y; Hidaka M; Morinaga S; Hashiyama M; Ogata M; Otsuka E; Takatsuka Y; Okamoto Y; Matsushita K; Okamura T; Tomoyose T
  •  go-up   go-down


71. Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA, Radich JP, Bernstein ID, Meshinchi S: FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood; 2006 Oct 15;108(8):2764-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
  • Acute myeloid leukemia (AML) is a clonal disease characterized by heterogeneous involvement of hematopoietic stem cell/progenitor cell populations.
  • Using FLT3 internal tandem duplication (FLT3/ITD) as a molecular marker, we tested the hypothesis that clinical outcome in AML correlates with disease involvement of CD34(+)/CD33(-) precursors.
  • Diagnostic specimens from 24 children with FLT3/ITD-positive AML were sorted by fluorescence-activated cell sorting (FACS), and resultant CD34(+)/CD33(-) and CD34(+)/CD33(+) progenitors were analyzed directly and after colony-forming cell (CFC) assay for the presence of FLT3/ITD.
  • This study suggests that FLT3/ITD involvement in CD34(+)/CD33(-) precursors is heterogeneous and that detection of the mutation in the less-mature progenitor population may be associated with disease resistance.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Oct 1;104(7):1995-9 [15187030.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] J Exp Med. 1989 May 1;169(5):1721-31 [2469766.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1811-6 [1373089.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Genome Res. 1999 May;9(5):482-91 [10330128.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1345-9 [15959528.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2054-62 [16136168.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Leukemia. 2000 Apr;14(4):675-83 [10764154.001]
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3292-8 [12115363.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:179-98 [12194988.001]
  • [Cites] Blood. 2003 May 1;101(9):3398-406 [12506020.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2387-94 [12816873.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):431-5 [14617001.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):150-6 [14701777.001]
  • [Cites] Arch Med Res. 2003 Nov-Dec;34(6):507-14 [14734090.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):413-23 [8439493.001]
  • [Cites] PCR Methods Appl. 1994 Jun;3(6):317-9 [7522723.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2154-61 [7536493.001]
  • [Cites] Blood. 1995 May 15;85(10):2643-53 [7742522.001]
  • [Cites] N Engl J Med. 1987 Aug 20;317(8):468-73 [3614291.001]
  • (PMID = 16809615.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 114563; United States / NCI NIH HHS / CA / 5T32 CA 009351-27; United States / NCI NIH HHS / CA / U10 CA 98543; United States / NCI NIH HHS / CA / R21 CA 102624; United States / NCI NIH HHS / CA / R01 CA114563; United States / NCI NIH HHS / CA / R01 CA 092316; United States / NCI NIH HHS / CA / U24 CA 114766
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC1895585
  •  go-up   go-down


72. Ghosh S, Bandyopadhyay S, Pal S, Das B, Bhattacharya DK, Mandal C: Increased interferon gamma production by peripheral blood mononuclear cells in response to stimulation of overexpressed disease-specific 9-O-acetylated sialoglycoconjugates in children suffering from acute lymphoblastic leukaemia. Br J Haematol; 2005 Jan;128(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased interferon gamma production by peripheral blood mononuclear cells in response to stimulation of overexpressed disease-specific 9-O-acetylated sialoglycoconjugates in children suffering from acute lymphoblastic leukaemia.
  • Disease-specific over-expression of 9-O-acetylated sialoglycoconjugates (9-O-AcSGs) on peripheral blood mononuclear cells (PBMC) of children with acute lymphoblastic leukaemia (ALL, PBMC(ALL)) has been demonstrated using a lectin, Achatinin-H, with specificity towards 9-O-AcSAalpha2-6GalNAc.
  • [MeSH-major] Glycoconjugates / metabolism. Interferon-gamma / immunology. Leukocytes, Mononuclear / chemistry. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Sialic Acids / metabolism
  • [MeSH-minor] Adolescent. Cell Proliferation. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay / methods. Female. Flow Cytometry. Humans. Infant. Lectins / metabolism. Male. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / physiology. Stimulation, Chemical

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606547.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoconjugates; 0 / Lectins; 0 / RNA, Messenger; 0 / Sialic Acids; 0 / achatinin(H); 55717-54-9 / 9-O-acetyl-N-acetylneuraminic acid; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


73. Yadav SP, Kalra M, Anjan M, Sachdeva A: Survival outcome in childhood acute lymphoblastic leukemia in India. Pediatr Blood Cancer; 2010 Jan;54(1):178; author reply 179
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival outcome in childhood acute lymphoblastic leukemia in India.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


74. Rabin KR, Man TK, Yu A, Folsom MR, Zhao YJ, Rao PH, Plon SE, Naeem RC: Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Aug;51(2):171-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Accurate detection of recurrent chromosomal abnormalities is critical to assign patients to risk-based therapeutic regimens for pediatric acute lymphoblastic leukemia (ALL).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 1995 May;13(1):54-61 [7541644.001]
  • [Cites] Leukemia. 2004 May;18(5):939-47 [14999294.001]
  • [Cites] Cancer Genet Cytogenet. 1998 May;103(1):20-4 [9595040.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3413-22 [15381628.001]
  • [Cites] J Med Genet. 2005 Feb;42(2):121-8 [15689449.001]
  • [Cites] Br J Haematol. 2005 May;129(4):520-30 [15877734.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Genes Chromosomes Cancer. 2006 May;45(5):482-94 [16425296.001]
  • [Cites] Br J Haematol. 2006 Nov;135(4):492-9 [16999846.001]
  • [Cites] J Mol Diagn. 2006 Nov;8(5):528-33 [17065418.001]
  • [Cites] PLoS One. 2007;2(3):e327 [17389918.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Sep;46(9):805-12 [17539022.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1613-9 [7564498.001]
  • [CommentIn] Pediatr Blood Cancer. 2008 Aug;51(2):153-4 [18300321.001]
  • (PMID = 18253961.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA090433; United States / NCI NIH HHS / CA / CA90433-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS570929; NLM/ PMC4063297
  •  go-up   go-down


75. Forestier E, Schmiegelow K, Nordic Society of Paediatric Haematology and Oncology NOPHO: The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol; 2006 Aug;28(8):486-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations.
  • The correlation between age and karyotype was studied in 1425, 0 to 14.9 years old children who were diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia.
  • Almost 80% of the non-Down B-cell precursor ALL cases in the 2 to 7 years frequency peak group who had aberrant cytogenetic results had either a high-hyperdiploid clone (51 to 61 chromosomes) or a translocation t(12;21)(p13;q22).
  • Among B-cell precursor ALL cases, high white blood cell counts correlated with earlier age at diagnosis (rS=-0.23; P<0.001) being most evident for 11q23/MLL-aberrations, translocation t(12;21)(p13;q22), and high-hyperdiploidy.
  • Among acute myeloblastic leukemia patients, frequency peaks were found for those with MLL/11q23 rearrangements (peak: first year), Down syndrome (peak: second to third year), or cytogenetic abnormalities other than translocations t(8;21), t(15;17), and inv(16)/t(16;16) (peak: first to third year).
  • The epidemiology of the cytogenetic subsets of acute leukemias questions whether age as a disease-related prognostic parameter has any relevance in childhood leukemia clinical research beyond being a surrogate marker for more important, truly biologic features such as cytogenetic aberrations and white cell count at diagnosis.
  • Further research is needed to explore whether the 2 to 7 years age incidence peak in childhood ALL harbor yet unidentified cytogenetic subsets with the same natural history as the high-hyperdiploid and t(12;21)-positive leukemias.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912588.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Anirudhan D, Bakhshi S, Xess I, Broor S, Arya LS: Etiology and outcome of oral mucosal lesions in children on chemotherapy for acute lymphoblastic leukemia. Indian Pediatr; 2008 Jan;45(1):47-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiology and outcome of oral mucosal lesions in children on chemotherapy for acute lymphoblastic leukemia.
  • Microbiological cultures were taken from oral cavity and blood in 100 mucositis episodes in 70 children with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Mouth Mucosa / microbiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Stomatitis / microbiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250506.001).
  • [ISSN] 0019-6061
  • [Journal-full-title] Indian pediatrics
  • [ISO-abbreviation] Indian Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


77. Forman SJ: Should patients with acute lymphoblastic leukemia receive hematopoietic stem-cell transplant from an unrelated donor? Nat Clin Pract Oncol; 2005 Jan;2(1):18-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should patients with acute lymphoblastic leukemia receive hematopoietic stem-cell transplant from an unrelated donor?
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Transplantation, Autologous. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264849.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


78. Ryningen A, Stapnes C, Bruserud Ø: Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leuk Res; 2007 Sep;31(9):1303-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
  • Differentiation-inducing therapy with the DNA-methylation inhibitor Decitabine (5'-aza-deoxycytidine) and histone deacetylase (HDAC) inhibitors are now considered in acute myelogenous leukemia (AML).
  • The colonies showed differences in morphology, viability, cell cycle distribution and expression of differentiation markers.
  • Both Decitabine and the two HDAC inhibitors altered AML cell expression of differentiation markers, whereas the drugs did not have any major influence on cell cycle distribution.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Differentiation. Epigenesis, Genetic / drug effects. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cell Cycle / drug effects. Cell Proliferation. DNA, Mitochondrial / metabolism. Enzyme Inhibitors / pharmacology. Female. Histone Deacetylase Inhibitors. Humans. Hydroxamic Acids / pharmacology. Male. Middle Aged. Myelodysplastic Syndromes / drug therapy. Phenylbutyrates / pharmacology. Thymidine / metabolism. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416413.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Mitochondrial; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Phenylbutyrates; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; 7WY7YBI87E / 4-phenylbutyric acid; M801H13NRU / Azacitidine; VC2W18DGKR / Thymidine
  •  go-up   go-down


79. Wolach B, Ash S, Gavrieli R, Stark B, Yaniv I, Roos D: Acute lymphoblastic leukemia in a patient with chronic granulomatous disease and a novel mutation in CYBB: first report. Am J Hematol; 2005 Sep;80(1):50-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia in a patient with chronic granulomatous disease and a novel mutation in CYBB: first report.
  • We report for the first time a child with chronic granulomatous disease (CGD) who developed acute lymphoblastic leukemia (ALL).
  • He was found to have a deficiency of the gp91(phox) subunit of the leukocyte NADPH oxidase, with the X-linked inheritance of the disease.
  • DNA analysis revealed a C nucleotide insertion between C1028 and T1029.
  • At the age of 16 months, the patient developed T-cell ALL.
  • He was treated for 2 years, and today, 10 years since the diagnosis, he is disease-free.
  • [MeSH-major] Granulomatous Disease, Chronic / genetics. Membrane Glycoproteins / genetics. Mutation. NADPH Oxidase / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Chronic Granulomatous Disease.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16138344.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CYBB protein, human; 0 / Membrane Glycoproteins; EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


80. Vanura K, Vrsalovic MM, Le T, Marculescu R, Kusec R, Jäger U, Nadel B: V(D)J targeting mistakes occur at low frequency in acute lymphoblastic leukemia. Genes Chromosomes Cancer; 2009 Aug;48(8):725-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] V(D)J targeting mistakes occur at low frequency in acute lymphoblastic leukemia.
  • Translocations of proto-oncogenes to the B-cell or T-cell antigen receptor loci in acute T- or B-cell leukemia and lymphoma have been, in most cases, accredited to V(D)J or switch recombination depending on the location of the breakpoint at the receptor locus.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogenes / genetics. Recombination, Genetic. Translocation, Genetic. VDJ Recombinases / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Animals. Cells, Cultured. DNA Breaks. DNA-Binding Proteins / genetics. Fibroblasts. Genes, T-Cell Receptor. Homeodomain Proteins / genetics. LIM Domain Proteins. Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / genetics. Metalloproteins / genetics. Mice. Receptors, Antigen, B-Cell / genetics. TCF Transcription Factors / genetics. Transcription Factor 7-Like 1 Protein

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455608.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / LIM Domain Proteins; 0 / Lmo2 protein, mouse; 0 / Metalloproteins; 0 / Receptors, Antigen, B-Cell; 0 / TCF Transcription Factors; 0 / Tcf7l1 protein, mouse; 0 / Tlx1 protein, mouse; 0 / Transcription Factor 7-Like 1 Protein; EC 2.7.10.2 / Lymphocyte Specific Protein Tyrosine Kinase p56(lck); EC 2.7.7.- / VDJ Recombinases
  •  go-up   go-down


81. Ohnishi K: PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int J Clin Oncol; 2007 Oct;12(5):313-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
  • Acute promyelocytic leukemia (APL) is characterized by generation of the PML-RARalpha fusion gene.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Benzoates / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oncogene Proteins, Fusion / antagonists & inhibitors. Oxides / therapeutic use. Tetrahydronaphthalenes / therapeutic use. Tretinoin / therapeutic use

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S65-71 [11587370.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):705-13 [12209159.001]
  • [Cites] Cell. 1997 May 2;89(3):373-80 [9150137.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):181-93 [11902573.001]
  • [Cites] Int J Hematol. 2005 Oct;82(3):224-9 [16207595.001]
  • [Cites] Blood. 1997 Aug 1;90(3):967-73 [9242525.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):78-85 [9440726.001]
  • [Cites] Ann Intern Med. 2000 Dec 5;133(11):881-5 [11103058.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1454-63 [12886231.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:156-61, 514 [17124055.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] J Biol Chem. 1992 Oct 25;267(30):21486-91 [1328234.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7257-65 [11704854.001]
  • [Cites] Blood. 2007 Jul 1;110(1):59-66 [17374742.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4222-4 [12010830.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]
  • [Cites] J Med Chem. 1988 Nov;31(11):2182-92 [3184125.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]
  • [Cites] Cell. 1991 Aug 23;66(4):663-74 [1652368.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3019-25 [15604216.001]
  • [Cites] J Cancer Res Clin Oncol. 1995;121(11):696-8 [7593136.001]
  • [Cites] Leukemia. 2002 Apr;16(4):617-22 [11960341.001]
  • [Cites] Nature. 1995 Oct 5;377(6548):454-7 [7566127.001]
  • [Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]
  • [Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1927-32 [12357344.001]
  • [Cites] Nature. 1989 Jun 29;339(6227):714-7 [2544807.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]
  • [Cites] Blood. 1993 Sep 1;82(5):1573-7 [8395911.001]
  • [Cites] Science. 2002 Feb 8;295(5557):1079-82 [11834837.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4131-43 [10361110.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):485-93 [16937107.001]
  • [Cites] Int J Hematol. 2000 Dec;72(4):470-3 [11197214.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Arch Biochem Biophys. 1980 Feb;199(2):374-83 [7362233.001]
  • [Cites] Ann Intern Med. 1996 May 15;124(10):893-6 [8610919.001]
  • [Cites] Blood. 1996 Jan 15;87(2):725-33 [8555497.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1202-6 [7858250.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:147-55 [17124054.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5 [9811311.001]
  • (PMID = 17929112.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Benzoates; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / Tetrahydronaphthalenes; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 08V52GZ3H9 / tamibarotene; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 46
  •  go-up   go-down


82. Radomska HS, Bassères DS, Zheng R, Zhang P, Dayaram T, Yamamoto Y, Sternberg DW, Lokker N, Giese NA, Bohlander SK, Schnittger S, Delmotte MH, Davis RJ, Small D, Hiddemann W, Gilliland DG, Tenen DG: Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med; 2006 Feb 20;203(2):371-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
  • Mutations constitutively activating FLT3 kinase are detected in approximately 30% of acute myelogenous leukemia (AML) patients and affect downstream pathways such as extracellular signal-regulated kinase (ERK)1/2.
  • In contrast, there was no effect when serine 21 was mutated to aspartate (S21D), which mimics phosphorylation of C/EBPalpha.
  • Thus, our results suggest that therapies targeting the MEK/ERK cascade or development of protein therapies based on transduction of constitutively active C/EBPalpha may prove effective in treatment of FLT3 mutant leukemias resistant to the FLT3 inhibitor therapies.


83. Ghez D, Rubio MT, Maillard N, Suarez F, Chandesris MO, Delarue R, Deau-Fischer B, Varet B, Hermine O, Buzyn A: Rapamycin for refractory acute graft-versus-host disease. Transplantation; 2009 Nov 15;88(9):1081-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin for refractory acute graft-versus-host disease.
  • Steroid-refractory acute graft-versus-host disease (GVHD) remains a significant cause of mortality after allogeneic stem-cell transplantation and therapeutic options are not codified.
  • METHODS: In this retrospective single-center study, 22 patients were identified, from October 2004 to February 2008, as having received rapamycin for acute GVHD refractory to one or more lines of treatment.
  • CONCLUSION: Despite a small and heterogeneous population of patients, these results are encouraging and provide a rationale for prospective studies that use rapamycin in steroid-refractory acute GVHD as a second- or third-line agent.
  • [MeSH-major] Graft vs Host Disease / drug therapy. Hematopoietic Stem Cell Transplantation / methods. Immunosuppressive Agents / therapeutic use. Leukemia / surgery. Sirolimus / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Bacterial Infections / epidemiology. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Middle Aged. Retrospective Studies. Survival Rate. Survivors. Transplantation, Homologous. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898203.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


84. Chakraborty S, Sun CL, Francisco L, Sabado M, Li L, Chang KL, Forman S, Bhatia S, Bhatia R: Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol; 2009 Feb 10;27(5):791-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
  • PURPOSE: Therapy-related myelodysplasia or acute myelogenous leukemia (t-MDS/AML) is a lethal complication of autologous hematopoietic stem-cell transplantation (aHCT) for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).
  • These telomere alterations preceded the onset of t-MDS and were independent of other known risk factors associated with development of t-MDS/AML on multivariate analysis.


85. Steinberg JD, Olver CS, Davis WC, Arzt J, Johnson J, Callan R: Acute myeloid leukemia with multilineage dysplasia in an alpaca. Vet Clin Pathol; 2008 Sep;37(3):289-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia with multilineage dysplasia in an alpaca.
  • Based on their morphology, the cells were interpreted to be progranulocytes and myeloblasts, and a presumptive diagnosis of acute myeloid leukemia (AML) was made.
  • The blast cells accounted for 60% of the nucleated cell population on bone marrow aspirates, further supporting a diagnosis of AML with multilineage dysplasia.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18761521.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, Wingard JR, Rowley SD, Stroncek D, Gee AP, Horowitz MM, Anasetti C: Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant; 2007 Dec;13(12):1461-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival.
  • Few studies have tested the benefits of using peripheral blood stem cell (PBSC) grafts versus bone marrow (BM) grafts for unrelated donor transplantation.
  • We compared outcomes after 331 PBSC and 586 BM transplants in adults with leukemia and myelodysplastic syndrome (MDS) who were followed for a median of 3 years after transplantation.
  • PBSC recipients were less likely to have chronic myelogenous leukemia (CML) and more likely to have MDS, to have poor performance scores, and to be transplanted more recently.
  • Rates of grades 2-4 acute graft-versus-host disease (GVHD) (58% versus 45%, P < .001) and chronic GVHD (cGVHD) (56% versus 42%, P < .001) were significantly higher with PBSC than with BM transplants.
  • The 3-year probabilities of treatment-related mortality (TRM), leukemia recurrence, leukemia-free, and overall survival (OS) were similar in the 2 groups with 3-year leukemia-free survival rates of 30% and 32% after transplantation of PBSC and BM, respectively.
  • Unlike results after HLA-matched sibling donor PBSC transplants, we did not identify a survival advantage with PBSC grafts in patients receiving unrelated donor transplants for advanced leukemia.

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jun 15;95(12):3702-9 [10845900.001]
  • [Cites] Hum Immunol. 2007 Jan;68(1):30-40 [17207710.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):27-33 [11244435.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1739-45 [11535506.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1309-10 [11965278.001]
  • [Cites] Blood. 2002 Jul 15;100(2):415-9 [12091330.001]
  • [Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3128-34 [12384409.001]
  • [Cites] Bone Marrow Transplant. 2003 Jan;31(1):23-9 [12621503.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2459-64 [2350582.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Blood. 2005 Jan 15;105(2):548-51 [15367429.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5074-87 [16051954.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4288-90 [16946302.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):175-81 [11172139.001]
  • (PMID = 18022576.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA076518-08; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-08; United States / NCI NIH HHS / CA / U24-CA76518-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS35024; NLM/ PMC2267869
  •  go-up   go-down


87. Rowe JM: Graft-versus-disease effect following allogeneic transplantation for acute leukaemia. Best Pract Res Clin Haematol; 2008 Sep;21(3):485-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-disease effect following allogeneic transplantation for acute leukaemia.
  • The graft-versus-leukaemia effect is one of the most important biological effects to influence outcome in patients with acute leukaemia.
  • The recognition of this modality over the past three decades has led to far-reaching changes in the concept and conduct of allogeneic transplantation in acute myeloid leukaemia, and in the infusion of donor lymphocytes as a therapeutic modality.
  • Despite these conceptual advances, there is a considerable need for more structured prospective studies to optimally define the role of reduced-intensity transplantation in both acute myeloid and acute lymphoblastic leukaemia.
  • [MeSH-major] Graft vs Host Disease / immunology. Leukemia / immunology. Leukemia, Myeloid, Acute / immunology. Stem Cell Transplantation / adverse effects. Transplantation, Homologous / immunology
  • [MeSH-minor] Bone Marrow Transplantation / adverse effects. Bone Marrow Transplantation / mortality. Graft vs Leukemia Effect / immunology. Hematopoietic Stem Cells / immunology. Humans


88. Paulsson K, Heidenblad M, Mörse H, Borg A, Fioretos T, Johansson B: Identification of cryptic aberrations and characterization of translocation breakpoints using array CGH in high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia; 2006 Nov;20(11):2002-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of cryptic aberrations and characterization of translocation breakpoints using array CGH in high hyperdiploid childhood acute lymphoblastic leukemia.
  • High hyperdiploidy, characterized by non-random trisomies, is the largest cytogenetic subgroup in childhood acute lymphoblastic leukemia (ALL).
  • In conclusion, the array CGH analyses revealed putative leukemia-associated submicroscopic imbalances and rearrangements in 2/8 (25%) hyperdiploid ALLs.
  • [MeSH-major] Genomics / methods. In Situ Hybridization, Fluorescence / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic


89. Magrath I, Shanta V, Advani S, Adde M, Arya LS, Banavali S, Bhargava M, Bhatia K, Gutiérrez M, Liewehr D, Pai S, Sagar TG, Venzon D, Raina V: Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected]. Eur J Cancer; 2005 Jul;41(11):1570-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
  • In the 1970s, survival rates after treatment for acute lymphoblastic leukaemia (ALL) in children and young adults (less than 25 years) in India were poor, even in specialised cancer centres.
  • The introduction of a standard treatment protocol (MCP841) and improvements in supportive care in three major cancer centres in India led to an increase in the event-free survival rate (EFS) from less than 20% to 45-60% at 4 years.
  • Total white blood cell count (WBC) was the only statistically significant risk factor identified in multivariate analyses in two of the centres.
  • Comparison of patient characteristics with published series from Western nations indicated that patients from all three Indian centres had more extensive disease at presentation, as measured by WBC, lymphadenopathy and organomegaly.
  • The proportions of ALLs with precursor T-cell immunophenotypes, particularly in Chennai, were also increased, even when differences in the age distribution were taken into consideration (in <18-year olds, the range was 21.1-42.7%), and in molecular analyses performed on leukaemic cells from over 250 patients less than 21-years-old with precursor B-cell ALL, a lower frequency of TEL-AML1-positive ALL cases than reported in Western series was observed.
  • The worse outcome of treatment in Indian patients compared with recent Western series was probably due to the higher rate of toxic deaths in the Indian patients, and possibly also due to their more extensive disease - which is, at least partly, a consequence of delay in diagnosis.
  • The higher toxic death rates observed are likely to have arisen from a combination of more extensive disease at diagnosis, co-morbidities (e.g., intercurrent infections), differences in the level of hygiene achievable in the average home, poor access to acute care, and more limited supportive care facilities in Indian hospitals.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. India. Infant. Male. Multicenter Studies as Topic. Multivariate Analysis. Recurrence. Risk Factors. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Cancer. 2007 Feb;43(3):632. Raina, V [added]
  • (PMID = 16026693.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


90. van Scherpenzeel Thim V, Remacle S, Picard J, Cornu G, Gofflot F, Rezsohazy R, Verellen-Dumoulin C: Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function. Hum Mutat; 2005 Apr;25(4):384-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function.
  • We aimed to explore the possibility that germline alterations of HOX genes might be involved in childhood acute lymphoid malignancies.
  • A cohort of 86 children diagnosed with acute lymphoid malignancy was studied, 20 of them concurrently presenting a congenital anomaly of the skeleton.
  • While 13 changes were also observed in healthy controls, three variants were exclusively found in acute lymphoid malignancy cases.
  • These comprised the germline c.242A>T (p.Glu81Val) missense mutation of HOXD4, detected in two children diagnosed with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Germ-Line Mutation. Homeodomain Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776434.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 142981; RefSeq/ NM/ 014621
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HOXD1 protein, human; 0 / Homeodomain Proteins; 0 / Hoxd4 protein, mouse; 0 / Transcription Factors
  •  go-up   go-down


91. Roboz GJ: Treatment of acute myeloid leukemia in older patients. Expert Rev Anticancer Ther; 2007 Mar;7(3):285-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute myeloid leukemia in older patients.
  • Acute myeloid leukemia carries a dismal prognosis in patients over 60 years of age and, despite many clinical trials of both novel and conventional agents, there has been no significant improvement in overall survival during the last 30 years.
  • Deciding which older acute myeloid leukemia patients would benefit from intensive chemotherapy is difficult and efforts are underway to improve existing risk-assessment tools.
  • The role of hematopoietic stem cell transplantation in older patients is under investigation.
  • All patients over 60 years of age with acute myeloid leukemia should be encouraged to participate in a clinical trial if possible.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cytarabine / therapeutic use. Disease Management. Drug Design. Drug Resistance, Neoplasm. Farnesyltranstransferase / antagonists & inhibitors. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Neoplasm Proteins / antagonists & inhibitors. Prognosis. Randomized Controlled Trials as Topic. Receptor, Macrophage Colony-Stimulating Factor / antagonists & inhibitors. Receptor, Macrophage Colony-Stimulating Factor / therapeutic use. Risk Assessment. Signal Transduction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338649.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 04079A1RDZ / Cytarabine; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.10.1 / Receptor, Macrophage Colony-Stimulating Factor
  • [Number-of-references] 81
  •  go-up   go-down


92. Larmonie NS, Dik WA, Beverloo HB, van Wering ER, van Dongen JJ, Langerak AW: BMI1 as oncogenic candidate in a novel TCRB-associated chromosomal aberration in a patient with TCRgammadelta+ T-cell acute lymphoblastic leukemia. Leukemia; 2008 Jun;22(6):1266-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BMI1 as oncogenic candidate in a novel TCRB-associated chromosomal aberration in a patient with TCRgammadelta+ T-cell acute lymphoblastic leukemia.
  • [MeSH-major] Chromosome Aberrations. Leukemia-Lymphoma, Adult T-Cell / genetics. Nuclear Proteins / genetics. Proto-Oncogene Proteins / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, gamma-delta / genetics. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17989714.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BMI1 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


93. Ghosh S, Bandyopadhyay S, Mukherjee K, Mallick A, Pal S, Mandal C, Bhattacharya DK, Mandal C: O-acetylation of sialic acids is required for the survival of lymphoblasts in childhood acute lymphoblastic leukemia (ALL). Glycoconj J; 2007 Jan;24(1):17-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O-acetylation of sialic acids is required for the survival of lymphoblasts in childhood acute lymphoblastic leukemia (ALL).
  • Exploiting the selective affinity of Achatinin-H towards 9-O-acetylneuraminic acid(alpha2-6)GalNAc, we have demonstrated the presence of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on hematopoietic cells of children suffering from acute lymphoblastic leukemia (ALL), indicative of defective sialylation associated with this disease.
  • These Neu5,9Ac(2)-GPs are also capable of inducing disease-specific anti-Neu5,9Ac(2)-GPs antibodies in ALL children.
  • Additionally, we have observed that disease-specific anti-Neu5,9Ac(2)-GPs have altered glycosylation profile, and they are incapable of exerting a few Fc-glycosylation-sensitive effector functions.
  • [MeSH-major] Lymphocytes / metabolism. Lymphocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Sialic Acids / metabolism
  • [MeSH-minor] Acetylation / drug effects. Annexin A5 / metabolism. Caspase 3 / metabolism. Cell Survival / drug effects. Child. Hematopoietic System / cytology. Humans. Lectins / pharmacology. Models, Immunological. Nitric Oxide / biosynthesis. Nitric Oxide Synthase Type II / metabolism. Sialoglycoproteins / chemistry. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 2005 May 1;95(1):206-16 [15770663.001]
  • [Cites] Leukemia. 1999 Feb;13(2):309-12 [10025909.001]
  • [Cites] Immunol Lett. 1997 Dec;59(3):151-7 [9419022.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] Science. 1984 Aug 24;225(4664):844-6 [6206564.001]
  • [Cites] Int Immunol. 2005 Feb;17(2):177-91 [15629900.001]
  • [Cites] Zoology (Jena). 2004;107(1):49-64 [16351927.001]
  • [Cites] Glycoconj J. 2000 Jul-Sep;17(7-9):485-99 [11421344.001]
  • [Cites] Neurochem Res. 2002 Aug;27(7-8):583-92 [12374193.001]
  • [Cites] Int Rev Cytol. 1997;175:137-240 [9203358.001]
  • [Cites] Ann Hematol. 2005 Feb;84(2):76-84 [15338196.001]
  • [Cites] Clin Biochem. 2004 May;37(5):395-403 [15087256.001]
  • [Cites] Carbohydr Res. 1995 Mar 1;268(1):115-25 [7736461.001]
  • [Cites] Br J Haematol. 2005 Jan;128(1):35-41 [15606547.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):801-12 [11054061.001]
  • [Cites] Glycobiology. 2004 Oct;14(10):859-70 [15190007.001]
  • [Cites] Leuk Res. 1999 Sep;23 (9):803-9 [10475619.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):270-7 [15197782.001]
  • [Cites] Glycobiology. 2000 Jun;10(6):539-49 [10814695.001]
  • [Cites] Glycoconj J. 1999 Jun;16(6):307-17 [10579699.001]
  • [Cites] Methods. 1997 Jan;11(1):112-5 [8990096.001]
  • [Cites] Glycoconj J. 2001 Jul;18(7):529-37 [12151714.001]
  • [Cites] J Exp Med. 1993 Jan 1;177(1):213-8 [7678114.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Oct 29;148(2):795-801 [3689374.001]
  • [Cites] Biochim Biophys Acta. 1982 Feb 2;714(2):351-5 [6976798.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1535-41 [12486096.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1529-33 [12486095.001]
  • [Cites] Leukemia. 1999 Jan;13(1):119-25 [10049046.001]
  • [Cites] Leukemia. 2003 Feb;17(2):442-50 [12592345.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31517-25 [8940167.001]
  • [Cites] Leuk Res. 1999 May;23(5):433-9 [10374857.001]
  • [Cites] Virology. 1987 Oct;160(2):419-25 [3660588.001]
  • (PMID = 17146715.001).
  • [ISSN] 0282-0080
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Lectins; 0 / Sialic Acids; 0 / Sialoglycoproteins; 0 / achatinin(H); 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


94. Martins A, Cairoli H, Domínguez P, Martin S, Ortiz C, Potasznik J, Schenone N: [Nephromegaly: as unusual presentation of acute lymphoblastic leukemia in an infant]. Arch Argent Pediatr; 2008 Jun;106(3):263-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephromegaly: as unusual presentation of acute lymphoblastic leukemia in an infant].
  • [Transliterated title] Nefromegalia: forma de presentación infrecuente de leucemia linfoblástica aguda en un lactante.
  • Nephromegaly in infancy may be due to several causes, being the most relevant: renal polycystic autosomic recessive disease, venous renal thrombosis, deposit diseases, kidney tumors, nephrotic congenital syndrome and neoplastic infiltration.
  • Although renal infiltration is relatively frequent in acute lymphoblastic leukemia, nephromegaly is an unusual form of presentation in this pathology.
  • The case of a four-year-old patient, who presents bilateral nephromegaly and pancytopenia, is presented.
  • Acute Lymphoblastic Leukemia is diagnosed, initiating the corresponding chemotherapic treatment.
  • [MeSH-major] Kidney / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695841.001).
  • [ISSN] 1668-3501
  • [Journal-full-title] Archivos argentinos de pediatría
  • [ISO-abbreviation] Arch Argent Pediatr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


95. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A: Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia; 2008 Dec;22(12):2159-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
  • This study found that MS-275, a novel synthetic benzamide histone deacetylase inhibitor (HDACI), blocked Akt/mammalian target of rapamycin (mTOR) signaling in acute myelogenous leukemia (AML) HL60 and acute promyelocytic leukemia (APL) NB4 cells, as assessed by decreased levels of the phosphorylated (p)-Akt, p-p70 ribosomal S6 kinase (p70S6K) and p-S6K by western blot analysis.
  • Interestingly, further inactivation of mTOR by rapamycin analog RAD001 (everolimus) significantly enhanced MS-275-mediated growth inhibition and apoptosis of these cells in parallel with enhanced upregulation of p27(kip1) and downregulation of c-Myc.
  • In addition, RAD001 potentiated the ability of MS-275 to induce differentiation of HL60 and NB4 cells, as measured by the expression of CD11b cell surface antigens, as well as reduction of nitroblue tetrazolium.
  • Taken together, concomitant administration of an HDACI and an mTOR inhibitor may be a promising treatment strategy for the individuals with a subset of human leukemia.
  • [MeSH-major] Histone Deacetylase Inhibitors. Immunosuppressive Agents / pharmacology. Leukemia, Myeloid, Acute. Leukemia, Promyelocytic, Acute. Sirolimus / analogs & derivatives. Transcription Factors / antagonists & inhibitors
  • [MeSH-minor] Acetylation / drug effects. Animals. Apoptosis / drug effects. Apoptosis / physiology. Benzamides / pharmacology. CCAAT-Enhancer-Binding Proteins / genetics. Cell Differentiation / drug effects. Cell Differentiation / physiology. Cell Division / drug effects. Cell Division / physiology. Drug Synergism. Everolimus. Female. HL-60 Cells. Histone Deacetylase 1. Histone Deacetylases / metabolism. Histones / metabolism. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Multiprotein Complexes. Promoter Regions, Genetic / physiology. Proteins. Proto-Oncogene Proteins c-akt / metabolism. Pyridines / pharmacology. Signal Transduction / drug effects. Signal Transduction / physiology. TOR Serine-Threonine Kinases. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18784743.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / CCAAT-Enhancer-Binding Proteins; 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Immunosuppressive Agents; 0 / Multiprotein Complexes; 0 / Proteins; 0 / Pyridines; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; 142805-41-2 / CEBPE protein, human; 1ZNY4FKK9H / entinostat; 9HW64Q8G6G / Everolimus; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.5.1.98 / HDAC1 protein, human; EC 3.5.1.98 / Histone Deacetylase 1; EC 3.5.1.98 / Histone Deacetylases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


96. Kreft A, Springer E, Lipka DB, Kirkpatrick CJ: Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis. Acta Haematol; 2009;122(1):36-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
  • A 54-year-old female patient developed acute erythroleukemia after an 8-year course of primary myelofibrosis.
  • A bone marrow trephine biopsy disclosed 2 morphologically distinct areas of chronic primary myelofibrosis and acute erythroleukemia.
  • Although the activating JAK2-V617F mutation was not maintained in blasts of acute erythroleukemia, it was detectable in the chronic phase of primary myelofibrosis, indicating that this mutation did not play a role in the leukemic transformation of erythroid cells.
  • [MeSH-major] Janus Kinase 2 / genetics. Leukemia, Erythroblastic, Acute / genetics. Primary Myelofibrosis / complications. Primary Myelofibrosis / genetics
  • [MeSH-minor] Cell Transformation, Neoplastic / genetics. Fatal Outcome. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Acute Erythroleukemia.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel
  • (PMID = 19713696.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


97. MacKenzie J, Greaves MF, Eden TO, Clayton RA, Perry J, Wilson KS, Jarrett RF: The putative role of transforming viruses in childhood acute lymphoblastic leukemia. Haematologica; 2006 Feb;91(2):240-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The putative role of transforming viruses in childhood acute lymphoblastic leukemia.
  • Epidemiological evidence suggests that infection is involved in the etiology of common acute lymphoblastic leukemia, either by stimulating an inappropriate immune response or in the form of a classical transforming agent.
  • In an attempt to elucidate the role that infection is playing in this disease, we used representational difference analysis (RDA) to examine tumor samples for the presence of exogenous genomes.
  • These results suggest that it is unlikely that a single, direct transforming agent is involved in the pathogenesis of common acute lymphoblastic leukemia.
  • [MeSH-major] Cell Transformation, Viral. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology


98. Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M: Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol; 2008 Mar;83(3):226-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level.
  • Cyclosporine A (CsA) is the mainstay of pharmacologic prevention of acute graft-versus-host disease (GVHD).
  • We previously reported that continuous infusion of CsA with a target blood level between 250 and 400 ng/ml significantly increased the incidence of acute GVHD compared to twice-daily infusion with a target trough level between 150 and 300 ng/ml.
  • Thus, we raised the target level of CsA continuous infusion to 450-550 ng/ml.
  • We treated 33 patients with the higher target level (CsA500) and compared the efficacy and toxicity with those in the 33 historical control patients (CsA300 group).
  • The incidence of grades II-IV acute GVHD was significantly lower in the CsA500 group (27 vs. 52%, P = 0.033).
  • The target level of CsA was identified as an independent significant risk factor for grades II-IV acute GVHD (P = 0.039), adjusted for the presence of HLA mismatch.
  • We conclude that the toxicity of the continuous CsA infusion with a target level of 450-550 ng/ml is acceptable and the efficacy to prevent acute GVHD is significant.
  • [MeSH-major] Cyclosporine / blood. Cyclosporine / therapeutic use. Graft vs Host Disease / prevention & control. Hematopoietic Stem Cell Transplantation / methods
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Agents / therapeutic use. Chronic Disease. Female. Histocompatibility Testing. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / blood. Immunosuppressive Agents / therapeutic use. Incidence. Infusions, Intravenous. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Living Donors. Male. Methotrexate / therapeutic use. Middle Aged. Transplantation, Homologous. Whole-Body Irradiation

  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17918253.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


99. Alduaij A, Butera JN, Treaba D, Castillo J: Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature. Clin Lymphoma Myeloma Leuk; 2010 Dec;10(6):480-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
  • BACKGROUND: Acute T-cell leukemia/lymphoma (ATLL) is a post thymic (peripheral) T-cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Male. Middle Aged. Remission Induction. Transplantation, Homologous. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21156467.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


100. Kawaguchi H, Taketani T, Hongo T, Park MJ, Koh K, Ida K, Kobayashi M, Takita J, Taki T, Yoshino H, Bessho F, Hayashi Y: In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Leuk Lymphoma; 2005 Feb;46(2):273-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
  • Imatinib, the ABL kinase inhibitor, is used not only for Philadelphia chromosome-positive (Ph + ) chronic myelogenous leukemia, but also for Ph + acute lymphoblastic leukemia (ALL), although resistance to the drug tends to develop in an early stage of the clinical course.
  • We describe a childhood refractory Ph + ALL patient in whom progressive resistance to imatinib was correlated with the appearance of a mutation in the BCR-ABL kinase domain and in vitro drug resistance to imatinib as determined by the methyl-thiazol-tetrazolium (MTT) assay.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Genes, abl / genetics. Mutation, Missense. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Cell Survival / drug effects. Child. Humans. Imatinib Mesylate. Male. Philadelphia Chromosome






Advertisement